Document:

Prepared by R.R. Donnelley Financial -- EX-10.2

 Exhibit 10.2 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 EXECUTION COPY 

Patent Transfer & Exclusive Licence Agreement 
 between

 Ascendis Pharma A/S 
 as Licensor 

and 
 Sanofi-Aventis Deutschland GmbH 

as Licensee 

 CONTENTS 
  

							
			
	1.	 	 Interpretation
	  	 	1	  
			
	2.	 	 Sale, Purchase and Licence Grant
	  	 	9	  
			
	3.	 	 Technical Information
	  	 	12	  
			
	4.	 	 Development
	  	 	13	  
			
	5.	 	 Manufacturing and Commercialisation
	  	 	15	  
			
	6.	 	 Regulatory
	  	 	15	  
			
	7.	 	 Payments
	  	 	16	  
			
	8.	 	 Records and Auditing
	  	 	18	  
			
	9.	 	 Pharmacovigilance
	  	 	19	  
			
	10.	 	 Confidentiality
	  	 	19	  
			
	11.	 	 Prosecution, Maintenance and Defence
	  	 	20	  
			
	12.	 	 Improvements
	  	 	21	  
			
	13.	 	 Infringement
	  	 	22	  
			
	14.	 	 Warranties
	  	 	23	  
			
	15.	 	 Indemnification
	  	 	25	  
			
	16.	 	 Limitation of Liability
	  	 	26	  
			
	17.	 	 Term and Survival
	  	 	26	  
			
	18.	 	 Termination
	  	 	26	  
			
	19.	 	 Effect of Termination
	  	 	27	  
			
	20.	 	 Miscellaneous
	  	 	28	  
		
	schedule 1 : PATENTS	  	 	34	  
		
	schedule 2 : SHORT FORM PATENT LICENCE	  	 	35	  
		
	schedule 3 : TECHNICAL INFORMATION	  	 	36	  
		
	schedule 4 : DEVELOPMENT PLAN	  	 	44	  
		
	schedule 5 : LICENCES GRANTED TO ASCENDIS	  	 	45	  
		
	schedule 6 : ASCENDIS EMPLOYEES	  	 	46	  
		
	schedule 7 : LIST OF FILING COUNTRIES	  	 	47	  

  
 i 

 THIS PATENT TRANSFER & EXCLUSIVE LICENCE AGREEMENT (this “Agreement”) is
dated 15 December 2010 and made 
 BETWEEN: 
  

	(1)	ASCENDIS PHARMA A/S, (“Licensor” or “Ascendis”), a company registered in Denmark with its registered office at Tuborg, Boulevard 12, DK-2900 Hellerup, Denmark; and

  

	(2)	SANOFI AVENTIS DEUTSCHLAND GmbH, (“Licensee” or “Sanofi”), a company registered in Germany with its registered office at Industriepark Höchst 65926 Frankfurt am Main,
Germany. 

 Each a “Party” and together the “Parties”. 

Background: 
  

	(A)	Ascendis owns and controls proprietary rights, titles and interests in patents and technical information relating to Glp-1 and Glp-1 analogs, exendin-4 and exendin-4 analogs, glucagon and glucagon analogs, insulin and
insulin analogs and the TransCon technology platform. 

  

	(B)	Sanofi wishes to develop and to commercialise Glp-1 and Glp-1 analogs, exendin-4 and exendin-4 analogs, glucagon and glucagon analogs, insulin and insulin analogs and other products in and outside the field of diabetes
and certain diabetes-related metabolic disorders using the TransCon technology platform, and Ascendis wishes to sell certain patents rights to Sanofi and grant Sanofi certain exclusive or non-exclusive, worldwide, licences in respect of certain
other patent rights, on the terms and conditions of this Agreement. 

 THE PARTIES AGREE THAT: 

 

	1.	Interpretation 

  

	1.1	Definitions 

 “Affiliate” means any business Entity which from time to time Controls,
is Controlled by or is under common Control with a Party to this Agreement. 
 “Ascendis Development Plan Expenses” means the following
costs and expenses incurred by Ascendis after the Effective Date directly in connection with Ascendis’ activities in accordance with the Development Plan: 
  

	 	(a)	out-of-pocket costs associated with the conduct of any development activities performed by Ascendis, its Affiliates or by an Independent Third Party on behalf of Ascendis in accordance with the Development Plan (and for
clarity are not otherwise included as part of the Ascendis FTE Rate); 

  

	 	(b)	Ascendis FTE Costs; and 

  

	 	(c)	any other costs or expenses specifically identified and included in the Development Plan, which, for the avoidance of doubt may include, without limitation, pre-paid amounts. 

  
 1 

 “Ascendis FTE Costs” means, for all activities performed by Ascendis or its Affiliates in
accordance with the Development Plan or as otherwise directed in writing by Sanofi, the product of (i) the number of FTEs used by Ascendis or its Affiliates for such activities as set forth in the Development Plan or other written document
approved by Sanofi and (ii) the Ascendis FTE Rate. For the avoidance of doubt, [***]. 
 “Ascendis FTE Rate” means [***]
per FTE, which amount is fully burdened and includes without limitation, for each FTE, [***]. 
 “Ascendis Improvement” means any
Improvement which is developed, in-licensed, acquired or otherwise controlled by Ascendis or its Affiliates after the Effective Date. 
 “Business
Day” means a day (other than a Saturday or Sunday) on which banks are open for ordinary face to face banking business in Copenhagen, Frankfurt/Main and Paris. 

“Business Team” means three (3) personnel of Ascendis and/or its Affiliates, having the scientific, technical and business skills,
expertise and experience necessary to conduct the Ascendis Development Activities in accordance with the terms hereof. The names of the members of the Business Team as of the Effective Date are listed on Part I of schedule 6. 

“Control(led)(ling)” means the beneficial ownership of more than fifty per cent (50%) of the issued share capital or the legal power to
direct or cause the direction of the general management of the company, partnership or other Entity in question. 
 “Cover(ed)(ing)” means,
with respect to any Patent and the subject matter at issue, that, but for a licence granted under a Valid Claim of such Patent, the manufacture, development, use, sale, offer for sale or importation of the subject matter at issue would infringe such
Valid Claim, or in the case of a Patent that is patent application, would infringe a Valid Claim in a patent issued from such patent application if the currently pending claims of such patent application were to be issued as a patent. 

“Development Plan” means the technology transfer and development activities to be performed by Ascendis and Affiliates and the associated
timetable and Ascendis Development Plan Expenses to such activities. A preliminary overview of the Development Plan is set out in Schedule 4. No later than [***] after the Effective Date, the Parties will discuss in good faith and agree on a
detailed Development Plan description to be attached to this Agreement as an update of Schedule 4. The Development Plan may be amended from time to time by the JDC during the term hereof. 

“Diabetes” means [***]. 

“Diabetes-Related Metabolic Disorders” means [***]. 

“Diabetic Dyslipidemia” means [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 2 

 [***] or (ii) as may be defined in applicable treatment and/or regulatory guidelines in force from time to
time in the relevant country(ies). 
 “Diligent Efforts” means with respect to a Party the level of efforts and resources such Party would
typically exert in similar circumstances pursuing the development and commercialisation of a similar product with similar market potential taking into account the stage of development or commercialization, market potential and market size, the
product life cycle, the risk of development or commercialization of the Product, the cost effectiveness of efforts or resources, the competitiveness of alternative products that are or are expected to be in the marketplace, the scope and duration of
patent rights or other proprietary rights related to the Product, the profitability of the Product and alternative products and other relevant commercial factors. The efforts of each Party’s respective Affiliates and Sub-Licensees shall count
towards that Party’s own Diligent Efforts. 
 “Effective Date” means the date of this Agreement. 

“EMA” shall mean the European Medicines Agency or any successor agency with comparable responsibilities. 

“Entity” means, and includes, any person, firm or company or group of persons or unincorporated body. 

“Fatty Liver Disease” means [***]. 

“Glp-1 Product” means [***]. 

“Glucagon Product” means [***]. 

“Good Clinical Practice” means the applicable principles and guidelines for good clinical practice for drugs and medicinal products, as such
principles and guidelines are amended, implemented and supplemented from time to time, including without limitation those set out in the Harmonised Tripartite Guideline for Good Clinical Practice as finalised by the International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 
 “Good Laboratory Practice” means the
applicable principles and guidelines for good laboratory practice for drugs and medicinal products, as such principles and guidelines are amended, implemented and supplemented from time to time, including without limitation those set out in the OECD
Principles of Good Laboratory Practice published by the Organisation for Economic Co-Operation and Development. 

“Good Manufacturing Practice” means all applicable principles and guidelines for good manufacturing practice for drugs and medicinal
products, as such principles and guidelines are amended, implemented and supplemented from time to time, including without limitation as specified in the applicable provisions of (i) European Directive 2003/94/EC and further guidance as
published by the European Commission in Volume IV of “The rules governing medicinal products in the European Community” and (ii) Title 21 Parts 210 and 211 of the US Code of Federal Regulations (21 C.F.R., parts 210 and
211). 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 3 

 “Improvement” means any improvement, discovery, invention, development, enhancement,
modification, technical information, whether or not patentable, relating to Product and/or the Technology Platform as in existence on the Effective Date, that arises during the term of this Agreement, that a Party owns or for which it has a licence
to any related patent, know-how or intellectual property right and has the ability to grant to the other Party access, a licence or a sub-licence (as applicable) to such patent, know-how or intellectual property right on the terms and conditions set
forth herein without violating the terms of any agreement or other arrangement with any Independent Third Party existing at the time such Party would be required hereunder to grant to the other Party such access, licence or sub-licence. For clarity,
any products acquired or licensed by either Party from any Independent Third Party after the Effective Date shall not be an Improvement. 

“IND” means an investigational new drug application, as defined in 21 C.F.R. Section 312.3, obtained for purposes of conducting clinical
trials in accordance with the requirements of the United States Federal Food, Drug and Cosmetic Act and the regulations promulgated thereunder, including all supplements and amendments thereto; or the equivalent application to the EMA, the filing of
which is necessary to commence clinical testing of the Products in humans. 
 “IND Approval” means the approval of an IND by EMA, FDA or
other competent regulatory authority. 
 “Independent Third Party” means any Entity other than Ascendis, its Affiliates or its
Sub-Licensees or Sanofi, its Affiliates or its Sub-Licensees. 
 “Insulin Product” means
[***]. 
 “Initiation” of a Phase II or Phase III Trial shall mean dosing of the first patient with Product or matching placebo (as
applicable) in such Phase II or Phase III Trial. 
 “Intellectual Property Office” means the official local patent, trade mark or other
intellectual property registry in each part of the Territory responsible for granting, maintaining records of, patents, trade marks or other intellectual property and any instruments made in respect thereof. 

“Joint Improvements” means any Improvements conceived or generated jointly during the term of, and in connection with, this Agreement by
employees, agents, or service providers of both Ascendis and Sanofi or their respective Affiliates. Ascendis and Sanofi shall each own an undivided fifty per cent (50%) interest in any Joint Improvement. 

“Major Country” means [***]. 

“Manufacture” or “Manufacturing” means any manufacturing activity of any Product, or any ingredient thereof, including
manufacturing for clinical use or commercial sale, testing, handling, packaging and storage, ongoing stability tests and regulatory activities related to any of the foregoing. 

“Marketing Authorisation” means the authorisation issued by the relevant Regulatory Authority necessary to place on the market Product in any
country or regulatory jurisdiction, but for the avoidance of doubt shall not include pricing and reimbursement approvals or inclusion on the official list of reimbursable drugs. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 4 

 “Metabolic Syndrome” means the presence of [***] of the following: 

 

	 	(A)	[***] 

  

	 	(B)	[***] 

  

	 	(C)	[***] 

  

	 	(D)	[***] 

  

	 	(E)	[***] 

 as such criteria may be modified or completed by applicable treatment and/or
regulatory guidelines in force from time to time in the relevant country(ies). 
 “Net Sales” means, with respect to a given period of
time, the gross amount invoiced by Sanofi and its Affiliates, its Sub-Licensees and their distributors to bona fide Independent Third Party purchasers from the sale or distribution to bona fide Independent Third Parties of Product, provided such
Product is covered by a Valid Claim, less the following deductions and offsets: 
  

	 	(A)	normal and customary trade, cash and quantity discounts, allowances and credits actually allowed or paid, based on the invoiced price or net price to Independent Third Party purchasers, including cash coupons and
retroactive price reductions; 

  

	 	(B)	credits or allowances actually granted for damaged Products, returns or rejections of Product, price adjustments and billing errors, in each case not in excess of the selling price of the Product; 

 

	 	(C)	reasonable and customary rebates, charge backs and discounts (or equivalents thereof), based on the invoiced price or net price to Independent Third Party purchasers, granted to managed health care organizations,
pharmacy benefit managers (or equivalents thereof), federal, state/provincial, local and other governments, their agencies and purchasers and reimbursers; 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 5 

	 	(D)	transportation costs, including insurance, for outbound freight related to delivery of the Products to the extent billed separately on the invoice and paid by the buyer; and 

 

	 	(E)	sales taxes and other governmental charges (including value added tax, but solely to the extent not otherwise creditable or reimbursed) to the extent billed separately on the invoice and actually paid in connection with
the sale (but excluding what is commonly known as income taxes). 

 The methodology for calculating (A) – (E), on a
country-by-country basis, shall conform to IFRS consistently applied by Sanofi and its Affiliates across its product lines. 
 In the event a Product is
sold in combination with one or more other pharmaceutically active ingredient(s), Net Sales shall be calculated [***]. 
 With respect to any Product
that includes [***]. 
 For clarity, the [***] where Sanofi, or its Affiliate or Sub-Licensee has [***]. 

For clarity, the following shall not be included in “Net Sales”: (a) Products transferred for administration to patients enrolled in clinical
trials or distributed through a not-for-profit foundation at no charge to eligible patients, and (b) Product used as samples to promote additional Net Sales, in amounts consistent with normal business practices of Sanofi or its Affiliates or
Sub-Licensees. 
 “Non-Proprietary Peptide” means a Peptide which can be freely used without infringing third party rights. 

“Obesity” means [***] as may be modified or completed by applicable treatment and/or regulatory guidelines in force from time to time
in the relevant country(ies). 
 “Patents” means the Product Patents, the Technology Platform Patents and any patent that may in the future
Cover an Ascendis Improvement or a Joint Improvement. 
 “Peptide” means a polypeptide of [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 6 

 “Phase II Trial” means, with respect to a Product, any human clinical trial conducted in any
country that is designed (i) to evaluate the efficacy of the pharmaceutical product for a particular indication or indications in patient volunteers with the indication under study and to assess side effects or (ii) to support an
additional Phase II Trial or any Phase III Trial. 
 “Phase III Trial” means, with respect to a Product, any human clinical trial conducted
in any country after preliminary evidence suggesting acceptable efficacy and safety of the pharmaceutical product has been obtained in prior studies, which is intended to gather additional information to evaluate the overall safety and efficacy of
the pharmaceutical product and provide an adequate basis for physician labelling. 
 “Product” means (i) any product developed by
Sanofi incorporating (in whole or part) the Technology Platform and/or using the Product Patents and/or the Technology Platform Patents and/or any Ascendis Improvements and/or any Joint Improvements, and/or (ii) any Glp-1 Product, any Glucagon
Product or any Insulin Product or any combination of Glp-1 Product, Glucagon Product, Insulin Product and/or any product included within (i) above. 

“Product Patents” means the patents and patent applications listed in Part I of schedule 1 and any conversion, continuation, division, or
substitution thereof, and any patents issuing thereon, any reissues, re-examinations or extensions of such patents and any foreign counterparts of such patent applications and patents in any country in the Territory. 

“Product Technical Information” means the Technical Information owned or controlled by Ascendis relating specifically to Product. 

“Regulatory Approval” means all necessary approvals (including Marketing Authorisations, pricing and reimbursement approvals and inclusion on
the official list of reimbursable drugs, as applicable) for the sale of Product for one or more indications in a country or regulatory jurisdiction. 

“Regulatory Authority” means any national, supra-national, regional, state or local regulatory agency, department, bureau, commission,
council or other governmental entity in any jurisdiction in the Territory involved in the granting of Regulatory Approval for, or involved in the regulation of, pharmaceutical products. 

“Sanofi Improvement” means any Improvement conceived or generated solely by employees, agents or service providers of Sanofi or its
Affiliates, excluding (i) any Sanofi Medical Device and (ii) any Improvements in Manufacturing. 
 “Sanofi Medical Device” means
any instrument, apparatus, appliance, material or other article proprietary or exclusively licensed to Sanofi, including any existing software necessary for its proper application, and used by Sanofi to administer a pharmaceutical product in humans
or animals. 
 “Sub-Licensee” means any Entity that has been granted a sub-licence by either Party of its rights granted hereunder in
accordance with Clause 2.5. 
 “Technical Information” means all identifiable know-how, experience, data and other information in the
possession or control of a Party and which such Party is free to disclose to the other Party, whether in human or machine readable form and whether stored electronically or otherwise and which might reasonably be of commercial, scientific,
technical, regulatory or medical interest to the other Party for the research, development, marketing, manufacture, importation, distribution, sale and/or use of product and/or Products and/or the use of Technology Platform. 

  
 7 

 “Technology Platform” means the Technical Information proprietary to Ascendis (but not including
any Product Technical Information or Product Patents), which [***]. 
 “Technology Platform Patents” means the patents and patent
applications listed in Part II of Schedule 1 and any conversion, continuation, division, or substitution thereof, and any patents issuing thereon, any reissues, re-examinations or extensions of such patents and any foreign counterparts of such
patent applications and patents in any country in the Territory. 
 “Territory” means worldwide. 

“Trade Sale” means a sale (direct or indirect, either through merger or otherwise) to an Independent Third Party (excluding a financial
investor provided such financial investor is not affiliated to a pharmaceutical or biotechnology company) of (i) fifty per cent (50%) or more of the shares in Ascendis or (ii) the whole or substantial part of the business of Ascendis.
For clarity, the Parties agree that the Technology Platform constitutes a substantial part of the business of Ascendis. 
 “Transaction”
means any transaction relating to the Technology Platform [***]; but excluding (i) [***], and/or (ii) any licensing of the Technology Platform and/or Technology Platform Products by Ascendis for use on any Independent Third
Party’s proprietary products [***]. 
 “Valid Claim” means a claim of [***] that (i) has not been rejected, revoked
or held to be invalid or unenforceable by a court or other authority of competent jurisdiction, from which decision no appeal can be further taken or (ii) has not been finally abandoned, disclaimed or admitted to be invalid or unenforceable
through reissue or disclaimer. 
 “VAT” means value added tax as provided for in the Value Added Tax Act 1994 and legislation supplemental
thereto, TVA or any other system of value added tax as provided for in Council Directive 2006/112/EC applied in any Member State of the European Union and any other similar turnover, sales or purchase, tax or duty levied by any other jurisdiction
whether central, regional or local. 
  

	1.2	Construction 

 In this Agreement where the context admits: 

 

	 	(A)	references to any statute or statutory provisions shall be deemed to refer to those provisions as amended or re-enacted or as their application is modified by other provisions from time to time and any reference to a
statutory provision shall include any subordinate legislation made from time to time under that provision; 

  

	 	(B)	references to this Agreement or to any other agreement or document referred to in this Agreement mean this Agreement or such other agreement or document as may be amended, varied, supplemented, modified or novated from
time to time, and include the Schedules; 

  

	 	(C)	references to Clause(s) and Schedule(s) are references to Clause(s) and Schedule(s) of and to this Agreement, and each of the Schedules shall have effect as if set out in this Agreement; 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 8 

	 	(D)	the headings and sub-headings in this Agreement are inserted for convenience only and shall not affect the construction of this Agreement; 

 

	 	(E)	the singular includes the plural and vice versa, and references to the masculine, feminine and the neuter shall include all such genders; 

 

	 	(F)	references to any Party include its successors and permitted assigns; 

  

	 	(G)	where any statement is to the effect that Ascendis is not aware of any matter or circumstance, or is a statement qualified by the expression “so far as Ascendis is aware”, such statement shall refer to the
state of the actual knowledge of the Business Team or of any other officer or key employee of Ascendis or its Affiliates, after reasonable investigation. 

  

	 	(H)	the symbol “€” means the lawful currency of the member states of the European Union that adopt the single currency in accordance with the EC Treaty, known as the “Euro”; and 

 

	 	(I)	throughout this Agreement, where the context permits, Ascendis shall mean Ascendis and its Affiliates. 

  

	2.	Sale, Purchase and Licence Grant 

  

	2.1	Ascendis hereby sells, assigns and transfers to Sanofi all right, title and interest in and to the Product Patents. Sanofi accepts such sale assignment and transfer. Ascendis shall as promptly as practicable after the
Effective Date (and no later than [***] thereafter), provide all declarations and sign, deliver and file all documents (or procure that such documents are signed, delivered and filed) that are necessary for the assignment and transfer of the
Product Patents and/or their re-registration in the name of Sanofi or a Sanofi Affiliate. Any costs associated solely with effectuating the assignment and transfer of the Product Patents shall be borne by Sanofi. 

 

	2.2	Subject to the terms and conditions contained herein, Sanofi hereby grants to Ascendis and its Affiliates a non-exclusive, royalty-free, licence (with the right to sub-license subject to Clause 2.5) in the Territory
under any Sanofi Improvements and its interest in any Joint Improvements to research, develop, market, manufacture, import, distribute, sell and use products (excluding any Product) outside Diabetes. 

 

	2.3	Subject to the terms and conditions of this Agreement, Ascendis hereby grants to Sanofi: 

  

	 	(A)	an exclusive (even as to Ascendis), royalty-free, licence (with the right to grant sub-licences subject to Clause 2.5) in the Territory to the Technology Platform Patents, the Technology Platform, the Ascendis
Improvements and its interest in the Joint Improvements to research, develop, market, manufacture, import, distribute, sell and use: 

  

	 	(1)	Glp-1 Product, Glucagon Product, Insulin Product and any combination of Glp-1 Product, Glucagon Product and/or Insulin Product for all diseases in humans and animals. 

 

	 	(2)	Products (other than Glp-1 Product, Glucagon Product, Insulin Product and any combination of Glp-1 Product, Glucagon Product and/or Insulin Product) for Diabetes in humans and animals. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 9 

	 	(B)	a non-exclusive, royalty-free licence (with the right to grant sub-licences subject to Clause 2.5) in the Territory to the Technology Platform Patents, the Technology Platform, the Ascendis Improvements and its interest
in the Joint Improvements to research, develop, market, manufacture, import, distribute, sell and use Products (other than Glp-1 Product, Glucagon Product, Insulin Product and any combination of Glp-1 Product, Glucagon Product and/or Insulin
Product) for Diabetes-Related Metabolic Disorders and Obesity in humans and animals, provided that: 

  

	 	(1)	if such Products are Peptides, they must first be developed by Sanofi for Diabetes or Obesity in humans and animals and the first Marketing Authorisation for such Products must be for Diabetes or Obesity in humans in a
Major Country; provided, however, that the foregoing shall not prevent Sanofi from developing such Products in Diabetic Related Metabolic Disorders before having completed development in Diabetes or Obesity. 

 

	 	(2)	if such Products are not Peptides, they must first be developed by Sanofi for Diabetes in humans and animals and the first Marketing Authorisation for such Product must be for Diabetes in humans in a Major Country;
provided, however, that the foregoing shall not prevent Sanofi from developing such Products in Diabetic Related Metabolic Disorders before having completed development in Diabetes. 

For clarity, the licences granted in Clause 2.3 do not include [***] and Products (other than Glp-1 Product, Glucagon Product, Insulin
Product and any combination of Glp-1 Product, Glucagon Product and/or Insulin Product) for use within the cardiovascular, oncology, ophthalmology, digestive systems and/or CNS areas, provided that nothing shall prevent Sanofi from researching,
developing, marketing, manufacturing, importing, distributing, selling and using (i) Glp-1 Product, Glucagon Product, Insulin Product and any combination of Glp-1 Product, Glucagon Product and/or Insulin Product in accordance with Clause
2.3(A)(1), or (ii) Product (other than Glp-1 Product, Glucagon Product, Insulin Product and any combination of Glp-1 Product, Glucagon Product and/or Insulin Product) for Diabetes in accordance with Clause 2.3(A)(2) or for any Diabetes Related
Metabolic Disorders and/or Obesity in accordance with Clause 2.3(B). For further clarity, nothing in this Agreement shall prohibit Ascendis or its Affiliates, Sub-Licensees or licensees from researching, developing, marketing, manufacturing,
importing, distributing, selling and using any product (other than Glp-1 Product, Glucagon Product, Insulin Product and any combination of Glp-1 Product, Glucagon Product and/or Insulin Product) for [***] and/or, for the avoidance of doubt,
any Diabetes Related Metabolic Disorders and/or Obesity. 
  

	2.4	The licence granted to Sanofi in Clause 2.3(B)(1) shall become exclusive on a Peptide by Peptide basis in respect of a specified Non-Proprietary Peptide if the following conditions are met: 

 

	 	(A)	Sanofi notifies Ascendis [***] for such Non-Proprietary Peptide; 

  

	 	(B)	Sanofi has been engaged [***] in respect of such Non-Proprietary Peptide in Diabetes or Obesity for at least a [***] period immediately preceding such notification, [***] to be justified and
documented by Sanofi; 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 10 

	 	(C)	Ascendis notifies Sanofi in writing that: 

  

	 	(1)	Ascendis, its Affiliates and Sub-Licensees have not [***] in respect of a such Non-Proprietary Peptide for at least a [***] period immediately preceding notification from Sanofi pursuant to Clause 2.4(A),
such [***] to be justified and documented by Ascendis; or 

  

	 	(2)	Ascendis has not granted a licence to such Non-Proprietary Peptide to a bona fide Independent Third Party prior to notification from Sanofi pursuant to Clause 2.4(A); 

such notification to be provided by Ascendis within [***] of notification from Sanofi pursuant to Clause 2.4(A); 

provided that nothing in this Clause 2.4 shall be deemed to change the scope of the licence granted in Clause 2.3. 

Following conversion of such licence to an exclusive licence in respect of such Non-Proprietary Peptide, if Sanofi abandons the development of
such Non-Proprietary Peptide, such licence shall become non-exclusive. In the event that Ascendis has declined Sanofi’s request for an exclusive licence for a Non-Proprietary Peptide and Ascendis subsequently abandons the development of such
Non-Proprietary Peptide, Sanofi shall then be entitled to an exclusive licence to such Non-Proprietary Peptide. 
  

	2.5	Each Party agrees that: 

  

	 	(A)	any and all sub-licences granted under Clauses 2.2 and 2.3 shall be on terms consistent with the terms of this Agreement, contain obligations on each Sub-licensee to perform and observe terms and conditions similar to
those contained herein so far as the same are applicable; 

  

	 	(B)	it shall be liable to the other Party for any acts and omissions of any its Sub-Licensee that cause any breach of the provisions of this Agreement; and 

 

	 	(C)	it shall, within thirty (30) days of the grant of each sub-licence, provide the other Party with a copy of such sub-licence, provided that the financials may be redacted.

  

	2.6	Ascendis shall, at the request and expense of Sanofi and where necessary, execute a formal licence agreement substantially in the form set out in schedule 2 and provide reasonable assistance to Sanofi for the purpose of
registering the exclusive patent licences granted pursuant to Clause 2.3 in respect of each patent at each relevant Intellectual Property Office in the Territory. For clarity, no compensation shall be due to Ascendis upon the execution of any such
formal licence agreement, other than reimbursement of Ascendis’ documented expenses. 

  

	2.7	 Sanofi’s Right of Information. During the term of this Agreement, Ascendis shall inform Sanofi about its research and development
activities relating to the Technology Platform. Such information shall take place during the meetings of the JDC for the term of the Development Plan, and thereafter [***]. The purpose of such information meetings shall be for Sanofi to be
timely informed about any opportunity that may appear to extend the relationship with Ascendis, including in connection with any proposed Transaction or Trade Sale. Prior to accepting any offer received from any Independent Third Party in relation
to any Transaction, Ascendis shall first notify Sanofi in writing of the existence of 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 11 

	 	
such offer and Sanofi shall be free to submit an offer to Ascendis. Ascendis shall consider in good faith any offer received from Sanofi, and within a reasonable period of time shall indicate to
Sanofi whether it is interested in pursuing discussions towards a potential Transaction with Sanofi. Any information received further to this Clause 2.7 shall remain subject to the confidentiality requirements set out in Clause 10. For clarity,
nothing in this Clause 2.7 may be interpreted as an obligation on Ascendis to disclose to Sanofi any information that is subject to any confidentiality obligation from time to time owed to any Independent Third Party. 

 

	2.8	Immunity from Suit. Sanofi hereby grants to Ascendis a free right (the “Immunity”) to practise any patent that may be applied for, filed by or delivered to Sanofi Covering an Improvement relating
to Manufacturing (a “Manufacturing Patent”) and/or an Improvement relating to any medical device that is not a Sanofi Medical Device (“Medical Device Improvement Patent”) outside Diabetes. The term of the Immunity
shall be for the duration of such Manufacturing Patent or Medical Device Improvement Patent, as applicable. The Immunity shall be transferable and/or extendable by Ascendis only to its licensees and/or Sub-Licensees for activities and products
outside Diabetes, without any right for such licensees or Sub-Licensees to themselves transfer or extend the Immunity to another party, including by way of business purchase, merger or otherwise. Ascendis shall promptly inform Sanofi in writing
after completion of any such transaction with such licensees and/or Sub-Licensees involving a transfer or extension by Ascendis of the Immunity hereby granted, and such notice shall include the identity of such licensees and/or Sub-Licensees and a
description of the therapeutic field (but not the financial terms) of the licences granted. For clarity, the Immunity hereby granted to Ascendis does not create any obligation on Sanofi to disclose to Ascendis any Technical Information relating to a
Manufacturing Improvement or to a Sanofi Medical Device. 

  

	2.9	Non-compete: During the term of this Agreement, and subject to expiry or termination of this Agreement, Ascendis shall not directly or indirectly engage, either by itself or on behalf of any Independent Third
Party, in any research, development or commercialization activities in connection with [***]. Subject to Clause 2.7, this Clause 2.9 shall not apply in respect of [***]. 

 

	3.	Technical Information 

  

	3.1	Within [***] of the Effective Date, Ascendis shall supply to Sanofi a copy of all Technical Information in Ascendis’ possession or control that is relevant to the Products and Diabetes in the Territory and
that has been disclosed to Sanofi up to and including on the Effective Date. Such Technical Information shall at least include the elements listed on schedule 3 and may be supplied in parts. 

 

	3.2	Upon request from Sanofi at any time and from time to time during the term of this Agreement, Ascendis will use its commercially reasonable efforts to provide Sanofi, or any Affiliate or Independent Third Party
designated by Sanofi, with any additional Technical Information relevant to the Products and Diabetes in the Territory in Ascendis’ possession or with on-site support as may be reasonably requested by Sanofi. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 12 

	3.3	Ascendis shall supply to Sanofi any Technical Information which comprises Ascendis Improvements and is relevant to the Products and Diabetes in the Territory, promptly after such Technical Information becomes available
to Ascendis during the term of this Agreement. 

  

	3.4	Nothing herein shall prevent Ascendis, its Affiliates or licensees from using any Technical Information including without limitation a right but not a obligation to use or refer (free of charge) to any regulatory or
other data forming part of any Technical Information among other things for the purposes of any regulatory filings provided that such use is not inconsistent with the rights of Sanofi granted hereunder. 

 

	3.5	Notwithstanding the foregoing, and for the purpose of the licence granted to Ascendis under Clause 2.2, Sanofi will supply to Ascendis a copy of all Technical Information which comprises Sanofi Improvements relevant to
products (excluding Technical Information which is exclusively relevant to Products) outside Diabetes in the Territory and that has not previously been disclosed to Ascendis. For clarity, nothing in this Agreement shall oblige Sanofi to supply to
Ascendis the registration file of any Product save to the extent that Technical Information is relevant for the general use of the Technology Platform. 

  

	3.6	Ascendis will, through the appropriate mechanisms, use Diligent Efforts to maintain existing employment of certain key employees identified by Sanofi as holding that Technical Information necessary for the performance
of the Development Plan and for the exercise of the rights granted to Sanofi to the Technology Platform. 

  

	4.	Development 

  

	4.1	Ascendis shall perform and complete, or cause the performance and completion, as the case may be, of the Development Plan activities set forth in schedule 4 (“Ascendis Development Activities”) and
deliver to Sanofi [***] arising therefrom within [***] following completion of the relevant studies as they are described in the Development Plan. As a condition to Sanofi making the payment of any of the three instalments referred to
under Clause 7.1(D), the Ascendis Development Activities will be conducted under the effective supervision of the Business Team. Any results of the Ascendis Development Activities shall be considered as Joint Improvements licensed to Sanofi under
Clause 2.3. 

  

	4.2	Joint Development Committee. 

  

	 	(A)	 Formation. Promptly after the Effective Date, the Parties will form a Joint Development Committee (the “JDC”) comprised of
Ascendis’ [***] and of [***] of Sanofi. One representative of Sanofi-Aventis at the JDC will be selected to act as the chairperson of the JDC. The JDC will meet at least [***] times per year during the term of the
Development Plan. Such meetings may be conducted by videoconference, teleconference or in person, as agreed by the Parties. The JDC will agree upon the time and location of the meetings. The chairperson, or his or her designee, will circulate an
agenda for each meeting approximately one week before the date scheduled for the meeting, and will include all matters requested to be included on such agenda by either Party. The chairperson, or his or her designee, will take complete and accurate
minutes of all discussions occurring at the JDC meetings and all matters decided upon at the meetings except that matters reflecting legal advice of counsel (including for clarity patent counsel) will not be included in such minutes. A copy of the
draft minutes of each meeting will be provided to each Party by the chairperson, or his or her designee, after each meeting, and such minutes will be reviewed by the JDC 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 13 

	 	
members, any needed changes discussed and final minutes agreed to and provided to each Party within thirty (30) days after each meeting unless otherwise agreed. A reasonable number of additional
representatives of a Party may attend meetings of the JDC in a non-voting capacity. Each Party is responsible for their travel costs and expenses associated with attending meetings. 

 

	 	(B)	JDC Functions and Powers. The responsibilities of the JDC will be as follows: 

  

	 	(1)	encouraging and facilitating communication between the Parties with respect to the development of Products; 

  

	 	(2)	reviewing the Development Plan, 

  

	 	(3)	monitoring the progress of the development of Products and each Party’s diligence in carrying out its responsibilities there under; and 

 

	 	(4)	carrying out the other duties and responsibilities described for it in this Agreement. 

  

	 	(C)	JDC Decision Making. All decisions of the JDC will be made by unanimous vote, with each member having one vote. If after reasonable discussion and consideration of each of the Parties’ views on a particular
matter before the JDC, the JDC is unable to reach a decision by unanimous vote on that matter, then [***]; provided, however, that in no event shall [***] in a manner that (a) materially impairs or is reasonably likely to impair
any rights or assets [***], or (b) results or is reasonably likely to result in (i) an increase in the scope of the [***] agreed by the Parties resulting in [***] or (ii) an [***]. The JDC shall not have
any authority other than that expressly set forth above and, specifically, shall have no authority (x) to amend or interpret this Agreement, (y) to determine whether or not a Party has met its diligence or other obligations under the
Agreement, or (z) to determine whether or not a breach of this Agreement has occurred. 

  

	 	(D)	Termination of JDC. The JDC shall terminate as of the earlier of (i) the acknowledgement by Sanofi that Ascendis has completed the Ascendis Development Activities, or (ii) the end of the [***]
period of time following the Effective Date. 

  

	4.3	Except for the specific work to be performed by Ascendis in the Development Plan, Sanofi shall assume and have the sole responsibility for all development (including associated costs) of Product in the Territory in
accordance with the provisions of this Agreement. 

  

	4.4	Sanofi reserves the right to approve (such approval not be unreasonable withheld) the appointment by Ascendis of any service providers intended to perform part of Ascendis’ Development Plan activities on behalf of
Ascendis. 

  

	4.5	 As part of the Technical Information to be provided by Ascendis hereunder, Ascendis shall promptly provide to Sanofi all information (including
copies, where applicable) of any current or future contracts between Ascendis or its Affiliates and any Independent Third Party suppliers or vendors that materially relate to the Development Plan or to the Products. At Sanofi’s request,
Ascendis shall use commercially reasonable efforts to assign or cause to be assigned (subject to assumption by Sanofi of the obligations) such agreements to Sanofi, to the extent that (i) such agreements relate solely to the

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 14 

	 	
development, manufacture and/or supply of Products and (ii) such assignment is permitted in accordance with the terms and conditions of such agreements or with the consent of the counterparty, or
Ascendis shall reasonably cooperate to assist Sanofi in obtaining the benefit of such agreements. 

  

	4.6	Ascendis will cooperate with Sanofi-Aventis to provide such reasonable technical assistance as may be necessary in connection with the transfer to Sanofi-Aventis of the development, manufacture and production of Product
as is consistent with the capacity and the capabilities of Ascendis. As part of such assistance, Ascendis will use commercially reasonable efforts to furnish, at Sanofi-Aventis’ reasonable request, a representative to attend drug regulatory
meetings regarding Product and/ or participate in activities related to such regulatory meetings. 

  

	4.7	The parties shall enter into good faith negotiations to agree a quality agreement within [***] of the Effective Date. 

  

	4.8	Sanofi undertakes to use Diligent Efforts to develop the First Product and the Second Product (as defined in Clause 7.1(C)) and to reach the milestones set forth in Clause 7.1(C)(1) to Clause 7.1(C)(8) inclusive, in the
Territory. For the avoidance of doubt, after Sanofi has made all the milestone payments set forth in Clause 7.1(C)(1) to Clause 7.1(C)(8) inclusive, the obligations set forth in this Clause 4.8 shall be satisfied and have no further force or effect.
Sanofi shall conduct all development of the Product in compliance with current Good Laboratory Practice, Good Clinical Practice and Good Manufacturing Practice (where applicable). 

 

	4.9	Sanofi shall keep Ascendis regularly and fully informed of the progress of development of Product as set forth in Clause 7.1(C). 

  

	5.	Manufacturing and Commercialisation 

  

	5.1	Sanofi shall be solely responsible for all Manufacturing and commercialisation activities relating to Product in the Territory. 

  

	5.2	Sanofi shall, and it shall procure that its Affiliates and any Sub-Licensees shall: 

  

	 	(A)	ensure that any packaging together with any inserts or material relating to the sale of Product are, marked, where practicable, with all relevant patent numbers of Patents and with a clear and prominent statement that
the Product incorporates the technology conceived by Ascendis; and 

  

	 	(B)	conduct all packaging and distribution in accordance with current Good Manufacturing Practice. 

  

	5.3	Sanofi undertakes to use Diligent Efforts to commercialise [***] in [***] and to reach the milestones set forth in Clause 7.1(C)(9) and Clause 7.1(C)(10). For the avoidance of doubt, after Sanofi has made
all the milestone payments set forth in Clause 7.1(C)(9) and Clause 7.1(C)(10), the obligations set forth in this Clause 5.3 shall be satisfied and have no further force or effect. 

 

	6.	Regulatory 

  

	6.1	Sanofi shall have the sole responsibility for obtaining and maintaining all Regulatory Approvals (including associated costs) for Product from Regulatory Authorities in each of the countries in the Territory.

  

	6.2	Sanofi undertakes to comply, and to procure that its Sub-Licensees comply, with all requirements of Regulatory Authorities and/or applicable law, regulation and guidance. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 15 

	7.	Payments 

  

	7.1	Sanofi shall make the following non-refundable purchase, licence fee and milestone payments to Ascendis: 

  

	 	(A)	Purchase price. In consideration of the purchase of the Product Patents, Sanofi shall pay Ascendis a non-refundable (subject to Section 19.4 hereunder), non-creditable one-time purchase price in the amount
of fifteen million Euros (Euro 15M). On or promptly after the Effective Date, Ascendis shall submit an invoice to Sanofi for such amount, and Sanofi shall pay such invoice within [***] after receipt of such invoice. 

 

	 	(B)	Licence Fee. In consideration of the rights and licences granted to Sanofi under the Technology Platform Patents, and other licence rights granted to it under this Agreement, Sanofi shall pay Ascendis a
non-refundable, non-creditable one-time licence fee in the amount of ten million Euros (Euro 10M). On or promptly after the Effective Date, Ascendis shall submit an invoice to Sanofi for such amount, and Sanofi shall pay such invoice within
[***] after receipt of such invoice. 

  

	 	(C)	Development and Sale Milestones. Sanofi shall pay Ascendis the following one-time milestone payments upon the first occurrence of each event set forth below achieved by Sanofi, its Affiliates, its Sub-Licensees
or their distributors: 

  

							
	 Milestone
N°
	  	 Description
	  	Amount (€)	 
	1	  	[***]	  	 	[***	] 
	2	  	[***]	  	 	[***	] 
	3	  	[***]	  	 	[***	] 
	4	  	[***]	  	 	[***	] 
	5	  	[***]	  	 	[***	] 
			
	6	  	[***]	  	 	[***	] 
			
	7	  	[***]	  	 	[***	] 
	8	  	[***]	  	 	[***	] 
	9	  	[***]	  	 	[***	] 
	10	  	[***]	  	 	[***	] 

 Should a First or Second Product [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 16 

 [***], the sum of the milestone payments [***] (i.e. [***]) would be paid
to Ascendis upon [***] for such Product. 
 In the event that the development of a First Product or a Second Product is suspended or
discontinued (each a “Suspended Product”), and another Product is developed instead of the Suspended Product (each a “Replacement Product”), any payments actually paid under Clause 7.1(C)(1) to Clause 7.1(C)(8),
inclusive, in respect of the Suspended Product shall not be due in respect of the Replacement Product but any payments not paid in respect of the Suspended Product shall be payable on the Replacement Product achieving the relevant milestone
described in Clause 7.1(C)(1) to Clause 7.1(C)(8), inclusive. For clarity, Sanofi may not be obliged to pay to Ascendis more than two-hundred and seventy million Euros (Euro 270M) under this Clause 7.1(C). 

For the avoidance of doubt, in the event that the milestones described in Clause 7.1(C)(9) and Clause 7.1(C)(10) are achieved in the same
calendar year, both payments shall be paid by Sanofi to Ascendis. 
 Sanofi shall provide Ascendis with written notice of the achievement of
any of the foregoing events within [***] thereafter. Upon receipt of such notice, Ascendis shall submit an invoice to Sanofi for the amount of such milestone payment, and Sanofi shall pay the respective payment for such event within
[***] after receipt of such invoice from Ascendis. For the avoidance of doubt, after Sanofi has paid any of the foregoing payments, Sanofi shall have no further obligation to make such payment again. 

 

	 	(D)	Funding of Ascendis Development Activities. Subject to the condition referred to under Clause 4.1, Sanofi will fund Ascendis Development Plan Expenses for activities to be performed by Ascendis under the
Development Plan, by paying the following three yearly instalments: 

  

	 	•	 	Year 1: [***] 

  

	 	•	 	Year 2: [***] 

  

	 	•	 	Year 3: [***] 

 The first yearly instalment shall be paid to Ascendis within
[***] of the Effective Date or [***] after the Parties agree on the Development Plan (to be attached as schedule 4), whichever is earlier, subject to receipt by Sanofi of the corresponding invoice to be issued by Ascendis. 

The second yearly instalment shall be paid to Ascendis [***], subject to receipt by Sanofi of the corresponding invoice to be issued by
Ascendis. 
 The third yearly instalment shall be paid to Ascendis [***], subject to receipt by Sanofi of the corresponding invoice
to be issued by Ascendis. 
 Such funding will cover [***] Ascendis Development Plan Expenses as described in the initial Development
Plan. The Parties will agree in writing on the payment of [***] Ascendis Development Expenses, before they are effectively incurred by Ascendis. For clarity, Ascendis shall not be obliged to incur costs in respect of the Development Plan in
any relevant year which are in excess [***] 
 [***] in accordance with this Clause 7.1(D). 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 17 

	7.2	All payments due under this Agreement shall be made in Euros to the credit of a bank account to be designated in writing by Ascendis. Conversion into Euros of any amounts under this Agreement will be made in a manner
consistent with Sanofi’s normal practices used to prepare its audited financial statements for internal and external reporting purposes, which uses a widely accepted source of published exchange rates. 

 

	7.3	Subject to Clause 7.4, Ascendis shall bear any and all taxes levied on account of any payment received under this Agreement. In the event that Sanofi is required, under applicable laws, to withhold any deduction or tax
from any payment due to Ascendis under this Agreement, such amount shall be deducted from the payment to be made by Sanofi, paid to the proper taxing authority, provided that Sanofi shall take reasonable and lawful actions to avoid and minimize such
withholding and promptly notify Ascendis so that Ascendis may take lawful actions to avoid and minimize such withholding. Each Party agrees to cooperate with the other Party in claiming exemptions from such deductions or withholdings under any
agreement or treaty from time to time in effect. 

  

	7.4	All sums payable by Sanofi under or pursuant to this Agreement are exclusive of VAT (if any). Accordingly, where any taxable supply for VAT purposes is made under or in connection with this Agreement by Ascendis to
Sanofi, Sanofi shall, in addition to any payment required for that supply, pay to Ascendis such VAT as is chargeable in respect of the supply at the same time as payment is due. Sanofi shall provide to Ascendis, prior to the due date for payment or
the raising of any invoice (whichever is the earlier), details of Sanofi’s own VAT registration number. Ascendis shall provide Sanofi with a valid VAT invoice in respect of any payment of VAT. 

 

	7.5	Where any fees, milestones or other sums payable by Sanofi to Ascendis hereunder remain unpaid after the date on which they became due, Sanofi shall pay to Ascendis interest calculated from the date upon which the sums
became due until payment thereof at the base lending rate of the European Central Bank ruling at the date the sums became due plus [***]. 

  

	7.6	Notwithstanding anything to the contrary contained herein, upon payment in full of the last milestone payment set forth in Clause 7.1(C) by Sanofi to Ascendis, the licences granted pursuant to Clause 2.3 shall be deemed
to be fully paid-up, royalty-free, perpetual and irrevocable. 

  

	8.	Records and Auditing 

  

	8.1	Each Party shall, and the Licensee shall procure that its Affiliates and Sub-Licensees shall, maintain complete and accurate books, records and accounts used for the determination of any payment obligations under this
Agreement, which books, records and accounts will be retained by such Party until [***] after the end of the period to which such books, records and accounts pertain. 

 

	8.2	 Each Party will have the right to have an independent certified public accounting firm of internationally recognized standing, reasonably acceptable
to the other Party, have access during normal business hours, and upon [***] prior written notice, to such of the records of the other Party and its Affiliates as may be reasonably necessary to verify the accuracy of any payment made or
received during the [***] prior to the date of such request; provided, however, that no Party will have the right to conduct more than one such audit in any [***] period. The accounting firm will disclose to the Parties only whether
the data reported by the audited Party are correct or incorrect and the 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 18 

	 	
specific details concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy in the auditing Party’s favour of more than
[***], in which case the audited Party will bear the cost of the audit. The results of such accounting firm will be final, absent manifest error. 

  

	8.3	If, based on the results of any audit, additional payments are owed Ascendis under this Agreement, then Sanofi will make such additional payments promptly after the accounting firm’s written report is delivered to
both Parties. If, based on the results of any audit, any payments made by Sanofi to Ascendis exceeded the amounts due and payable under this Agreement, then Ascendis will return such excess to Sanofi promptly after the accounting firm’s written
report is delivered to both Parties. 

  

	9.	Pharmacovigilance 

  

	9.1	Upon execution of this Agreement, the Parties shall promptly, and in any event before Sanofi starts any clinical development activities, agree on the terms of a safety data exchange agreement (the
“SDEA”) for the collection, reporting and exchange of safety information. The Parties shall immediately implement such SDEA and shall provide each other on a regular basis with any information which has become available to them and
which is relevant to the safe use of Product (or of product, where applicable). Such procedures shall also relate to Sanofi’s Affiliates and Sub-Licensees. 

  

	9.2	Each Party shall notify the other of a “serious adverse experience” or “unexpected adverse experience” (as defined below) and will manage the same in accordance with the terms of the SDEA. For the
purposes of this Clause 9.2, “serious adverse experience” shall mean any adverse event associated with the use of Product in humans (whether or not considered drug-related) that gives rise to one or
more of the following: death, threat to life, new or prolonged in-patient hospitalisation, permanent or significant disability or incapacitation, overdose, congenital abnormality, or serious laboratory abnormality which is thought by the reporting
physician to be serious or associated with relevant clinical signs or symptoms. An “unexpected adverse experience” shall mean any adverse event that is not identified in nature, severity, or frequency in the then current investigation
brochure for Product (or of product, where applicable) or approved prescribing information. 

  

	10.	Confidentiality 

  

	10.1	Sanofi agrees to keep secret Ascendis’ confidential Technical Information, Ascendis Improvements and all other confidential information that it may obtain from Ascendis, its Affiliates or licensees in the course of
this Agreement, to use the same exclusively as permitted under this Agreement, and to disclose the same only to those of its employees, contractors, consultants, Affiliates and Sub-Licensees to whom and to the extent that such disclosure is
reasonably necessary in accordance with this Agreement. 

  

	10.2	Ascendis agrees to keep secret Sanofi’s confidential Technical Information, Sanofi’s Improvements and all other confidential information that it may obtain from Sanofi, its Affiliates and Sub-Licensees in the
course of this Agreement, to use the same exclusively as permitted under this Agreement, and to disclose the same only to those of its employees, contractors, Affiliates and Sub-Licensees to whom and to the extent that such disclosure is reasonably
necessary in accordance with this Agreement. 

  

	10.3	The foregoing obligations of Clauses 10.1 and 10.2 shall not apply to Technical Information or other information which: 

  

	 	(A)	prior to receipt thereof from one Party was in the possession of the recipient Party and at its free disposal; 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 19 

	 	(B)	is subsequently disclosed to the recipient Party without any obligations of confidence by an Independent Third Party who has not derived it directly or indirectly from the disclosing Party; 

 

	 	(C)	is or becomes generally available to the public through no act or default of the recipient Party or its agents, contractors or employees; 

 

	 	(D)	is independently developed by the receiving Party without the benefit of any disclosure hereunder, as demonstrated by documented evidence prepared contemporaneously with such independent development; or

  

	 	(E)	is required to be disclosed by law, regulation or action of any governmental agency or authority. 

  

	10.4	Each Party shall procure that all its employees, contractors, Affiliates and Sub-Licensees who have access to any information of the other to which the obligations of Clauses 10.1 or 10.2 as the case may be apply, shall
be made aware of, subject to, and comply with those obligations. During the term of this Agreement, each Party shall [***] protect and prevent the misappropriation of Technical Information by any of its employees or contractors or any
Independent Third Party, including were appropriate by initiating legal action against any such employee, contractor or Independent Third Party, as applicable. 

  

	10.5	Each Party (“Publishing Party”) shall submit to the other Party manuscripts, including abstracts, and texts of poster presentations and other external presentations containing confidential Technical
Information or other information at least [***] prior to presentation or submission for publication for purposes of allowing the other Party to comment on the manuscript or text; provided that the other Party may require the Publishing Party,
by giving notice in writing to the Publishing Party within [***] of the receipt of such manuscript, abstract, text or other external presentations from the Publishing Party to stop submission for publication or presentation of such
manuscript, abstract, text or other external presentation if, in the reasonable opinion of the other Party such delay is necessary in order to permit the filing of any patent application or to protect commercially sensitive data in respect of some
or all of the other Party’s confidential information contained in such manuscript, abstract, text or other external presentation. 

  

	10.6	Promptly upon execution of this Agreement, each Party may issue an initial press release disclosing the execution of this Agreement and its contents, subject to the prior written consent of the other Party (which
consent shall not be unreasonably withheld or delayed) to the contents of such press release. Neither Party shall make any other press releases or other public announcement(s) or disclosures to any third party relating to this Agreement, or any term
hereof, without the prior written consent of the other Party (which consent shall not be unreasonably withheld or delayed), except where such disclosure is required by applicable law, in which case the disclosing party shall, to the extent permitted
by applicable law, provide copies of the disclosure reasonably in advance of such disclosure for the non-disclosing Party’s prior review and comment. 

  

	11.	Prosecution, Maintenance and Defence 

  

	11.1	Sanofi shall be responsible for filing, prosecuting and defending the Product Patents and any new patent Covering a Product, a Sanofi Improvement or a Joint Improvement. Ascendis shall, upon request by Sanofi and at the
expenses of Sanofi, provide reasonable assistance to Sanofi with regard to such filing, prosecution and defence activities. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 20 

	11.2	Subject to clause 11.3, Ascendis shall be responsible for filing, prosecuting, maintaining and defending the Technology Platform Patents and any patents Covering Ascendis Improvements. Ascendis will provide Sanofi with
drafts of all such proposed filings and correspondence (including without limitation the initial application as well as any material correspondence received from any Independent Third Parties or Intellectual Property Office related to any filings)
which are relevant to Diabetes in the Territory. Sanofi shall have [***] to review and comment on such filings and correspondence, unless the date of receipt by Ascendis of such filings and correspondence and the official deadline set by such
Intellectual Property Office is such that Sanofi’s period of review and comment should be shorter, in which case Ascendis shall provide such filings and correspondence as soon as practicable and inform Sanofi of such shorter period. Ascendis
shall consider all of Sanofi’s reasonable suggestions, recommendations and instructions concerning the preparation, filing, prosecution, defence and maintenance of the Technology Platform Patents (including without limitation any suggestion or
recommendation to alter or limit the scope, content and/or claims of any such application) and, to the extent otherwise practicable, shall undertake the preparation, filing, prosecution and defence of the Technology Platform Patents in a way that
will not be detrimental to the research, development or commercialization of any Products. Ascendis agrees to file the Technology Platform Patents and any new patent Covering the Ascendis Improvements thereto in each of the countries listed on
schedule 7 to the extent practicable. Ascendis shall not abandon or allow to lapse any Technology Platform Patent or any new patents Covering the Technology Platform or any Ascendis Improvements in Diabetes in any other country of the Territory
without first giving Sanofi the opportunity to [***], provided that maintenance of such patent will not in Ascendis’ reasonable opinion impair Ascendis’ intellectual property protection in any respect for the Technology Platform and
any products (other than Glp-1 Product, Glucagon Product, Insulin Product and any combination of Glp-1 Product, Glucagon Product and/or Insulin Product). 

  

	11.3	Ascendis shall bear the costs of filing, prosecuting, maintaining and defending the Technology Platform Patents. With effect from the Effective Date, Sanofi shall be responsible for the costs of filing, prosecuting,
maintaining and defending the Product Patents and any new patent Covering a Product, a Sanofi Improvement or a Joint Improvement. 

  

	11.4	Each Party agrees that it will conduct its filing, prosecution, maintenance and defence activities in relation to its patent applications and patents in a manner that is not detrimental to the other Party’s Patents
and/or to any patent applications filed by or granted to such other Party to Cover its Improvements. 

  

	12.	Improvements 

  

	12.1	Subject to the provisions of Clause 12.2, Ascendis shall own all right, title and interest in and to any and all Ascendis Improvements. Ascendis shall [***] be responsible for filing, prosecuting, maintaining and
defending any patent Covering Ascendis Improvements. 

  

	12.2	Any Ascendis Improvement which is necessary or useful for the development, manufacture or commercialization of a Product shall be included in the licences granted to Sanofi under Clause 2.3. 

 

	12.3	 Sanofi shall own all right, title and interest in and to any and all Sanofi Improvements. Sanofi shall [***] be responsible for filing,
prosecuting, maintaining and defending any patent claiming Sanofi Improvements. If Sanofi does not wish to maintain or defend any such patent or if Sanofi wishes to abandon any such patent or allow any

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 21 

	 	
such patent to lapse, and provided that maintenance of such patent will not in Sanofi’s reasonable opinion impair Sanofi’s intellectual property protection in any respect of Product or
Sanofi Improvement, Sanofi shall first offer in writing to Ascendis an opportunity to acquire such patent(s) with the right to use such patent(s) as it wishes, without compensation to Sanofi. 

 

	12.4	Any Sanofi Improvement which is necessary or useful for the development, manufacture or commercialization of a product (excluding Product) by Ascendis or relates to the Technology Platform shall be included in the
Technical Information and shall be included in the licence granted to Ascendis under Clause 2.2. 

  

	13.	Infringement 

  

	13.1	By an Independent Third Party 

  

	 	(A)	In the event of Sanofi or Ascendis becoming aware of any suspected infringement or any unauthorised use by an Independent Third Party of any of the Patents, Ascendis Improvements, Sanofi Improvements, Joint Improvements
or Technical Information in the Territory, the Party becoming aware of the same shall notify the other Party. 

  

	 	(B)	Where such suspected infringement or unauthorised use (i) is outside [***], Ascendis shall [***] have the exclusive right to take or threaten any legal action that it deems appropriate to halt such
suspected infringement and to retain any amounts recovered in respect of such suspected infringement or unauthorised use. 

  

	 	(C)	Where such suspected infringement relates to any [***] or to any [***], Sanofi shall [***] have the exclusive right to take or threaten any legal action that it deems appropriate to halt such
suspected infringement and to retain any amounts recovered in respect of such suspected infringement or unauthorised use. 

  

	 	(D)	Where such suspected infringement is within [***] but does not relate to any [***] or to any [***]: 

  

	 	(1)	the Parties shall consult with each other with reasonable diligence in order to consider whether legal action should be taken or threatened concerning such suspected infringement or unauthorised use; 

 

	 	(2)	if the Parties agree that legal action should be taken or threatened, then they shall share [***] the costs of threatening or taking such legal action and in any amounts recovered as a result of the taking of
such action unless the Parties otherwise agree in writing. In such circumstances, Sanofi shall have conduct of the action but shall consult Ascendis in good faith with regard to all significant decisions; 

 

	 	(3)	if Sanofi wishes to take or threaten legal action but Ascendis does not, then Sanofi may request Ascendis to lend its name where necessary or desirable to proceedings relating to such action and provide reasonable
assistance in such proceedings and Ascendis will do so subject to Sanofi [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 22 

 [***]. In such circumstances, Sanofi shall have conduct of the action but shall consult
Ascendis in good faith with regard to all significant decisions. In addition, Sanofi shall be [***]; and 
  

	 	(4)	in any event, neither Party shall take any steps to settle or compromise such legal action or to reject the same without the prior written consent of the other Party (such consent not to be unreasonably withheld or
delayed). 

  

	13.2	Against an Independent Third Party 

  

	 	(A)	In the event that the development or commercialisation of Product (or of products, where applicable) results in action by an Independent Third Party against a Party (or its Affiliates or Sub-Licensees) for infringement
or unauthorised use of intellectual property or confidential information anywhere in the Territory, such Party shall promptly notify the other Party in writing. 

  

	 	(B)	Each Party (or its Affiliates or Sub-Licensees) against whom such action is brought shall (i) have the right but not the obligation to defend such action, (ii) have the right to be represented by separate
legal advisors, (iii) keep the other Party informed of, and assist and co-operate with the other Party in, any such action and (iv) bear its own costs. 

 

	14.	Warranties 

  

	14.1	Each Party warrants to the other Party that: 

  

	 	(A)	it is free to enter into this Agreement and to carry out its obligations hereunder without violating any obligation owed by it or any of its Affiliates to any Independent Third Party; 

 

	 	(B)	it shall not, during the existence of this Agreement, enter into any assignments, licences, obligations, charges or assignments, either written, oral or implied, which are or shall be inconsistent with this Agreement;
and 

  

	 	(C)	it has obtained all necessary corporate approvals to enter into and execute this Agreement. 

  

	14.2	Ascendis represents and warrants to Sanofi, as of the Effective Date: 

  

	 	(A)	Ascendis has the right to grant the licence granted to Sanofi on the terms set forth in Clause 2.3; 

  

	 	(B)	schedule 1 accurately identifies all Patents owned by or licensed to Ascendis as of the Effective Date that claim a Product or its manufacture or use; 

 

	 	(C)	All application and renewal fees required for the maintenance of the Patents have been duly and timely paid; 

  

	 	(D)	 There is no pending litigation or claim served against Ascendis or any Affiliate of Ascendis that (i) alleges that any of Ascendis’ or any of its
Affiliates’ activities 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 23 

	 	
relating to the Products or the Platform Technology have violated, or by developing Products would violate, any of the intellectual property rights of any third party (nor has it received at its
corporate offices any written communication addressed to senior management threatening such litigation), or (ii) seeks to invalidate any of the Patents. During the term of this Agreement, Ascendis shall promptly notify Sanofi in writing upon
learning of any such threatened claim or litigation; 

  

	 	(E)	Ascendis owns all right, title and interest in and to, or holds a licence to, the Patents, free and clear of all encumbrances, security interests, options and licences; 

 

	 	(F)	Ascendis or its Affiliates (i) have obtained the assignment of all interests and all rights of its employees with respect to the Patents, and (ii) have taken reasonable measures to protect the confidentiality
of those items in the Ascendis Technical Information that are confidential; 

  

	 	(G)	So far as Ascendis is aware, there is no use, infringement or misappropriation of the Patents or the Ascendis Technical Information, in derogation of the rights granted to Sanofi in this Agreement; 

 

	 	(H)	All third party patents actually known to Ascendis that Ascendis believes would be infringed by the development or commercialization of the Product by Sanofi in accordance with this Agreement are identified in the
freedom to operate searches provided by Ascendis to Sanofi on or prior to the Effective Date; 

  

	 	(I)	So far as Ascendis is aware, there are no investigations, inquiries, actions or other proceedings pending before any Regulatory Authority or other government agency with respect to any Product, and Ascendis has not
received at its corporate offices any written notice addressed to senior management threatening any such investigation, inquiry, action or other proceeding. During the term of this Agreement, Ascendis shall promptly notify Sanofi in writing upon
learning of any such actual or threatened investigation, inquiry, action or proceeding; 

  

	 	(J)	schedule 5 accurately identifies all licences granted to Ascendis by any Independent Third Parties with respect to the Products, their formulation, Manufacture or use, and so far as Ascendis is aware, Ascendis is not in
breach or default under any such licence and has not received from any licensor any written notice of breach or default; 

  

	 	(K)	All employees of Ascendis and of its Affiliates (including without limitation each member of the Business Team) are individually bound to Ascendis or its Affiliates by written confidentiality undertakings during the
term of their employment with Ascendis or its Affiliates; 

  

	 	(L)	The employees listed in Part II of schedule 6 are individually bound to Ascendis by non-compete undertakings while they remain shareholders in Ascendis; and 

 

	 	(M)	Ascendis has disclosed in writing and/or made available to Sanofi for its review, all filings or material correspondence between Ascendis or its Affiliates and Regulatory Authorities and all study reports that are
related to any Glp-1 Product, Glucagon Product or any Insulin Product or any combination of Glp-1 Product, Glucagon Product and/or Insulin Product. 

  

	14.3	To the fullest extent permitted by law, Ascendis excludes all other warranties, express or implied, in respect of the Patents, Technical Information and Product, including without limitation any warranties in respect of
merchantability, fitness for purpose, satisfactory quality, completeness or accuracy. 

  

	14.4	Sanofi warrants that it has the commercial, technical and financial resources and expertise available, and intends to use them, to develop Product in the Territory as contemplated in Clause 4.3 of this Agreement.

  
 24 

	15.	Indemnification 

  

	15.1	Ascendis shall indemnify, defend and hold Sanofi and its Affiliates, and their respective directors, officers, employees and agents (each a “Sanofi Indemnitee”) from and against all losses, liabilities,
damages, settlements, claims, actions, suits, penalties, fines, costs or expenses (including reasonable attorney’s fees) to the extent relating to an Independent Third Party claim, action or demand (each a “Loss”) arising out
of or resulting from the negligence, recklessness, intentional acts or omissions in relation to this Agreement, or the performance of the Development Plan Activities, or the manufacture, supply, marketing, sale or use of products, or infringement of
intellectual property or misappropriation or unauthorised disclosure of confidential information by Ascendis or its Affiliates and their respective directors, officers, employees and agents, except to the extent such Independent Third Party claim,
action or demand arose or resulted from the negligence, recklessness, intentional acts or omissions of Sanofi or its Affiliates and their respective directors, officers, employees and agents in relation to this Agreement. 

 

	15.2	Except as provided in Clause 15.1 above, Sanofi shall indemnify, defend and hold Ascendis, its Affiliates, and their respective directors, officers, employees and agents (each a “Ascendis Indemnitee”)
from and against all losses, liabilities, damages, settlements, claims, actions, suits, penalties, fines, costs or expenses (including reasonable attorney’s fees) to the extent relating to an Independent Third Party claim, action or demand
(each a “Loss”) arising out of or resulting from the negligence, recklessness, intentional acts or omissions in relation to this Agreement, or the performance of the Development Plan Activities, or the manufacture, supply,
marketing, sale or use of product, or infringement of intellectual property or misappropriation or unauthorised disclosure of confidential information by Sanofi or its Affiliates or Sub-licensees, and their respective directors, officers, employees
and agents, except to the extent such Independent Third Party claim, action or demand arose or resulted from the negligence, recklessness, intentional acts or omissions of Ascendis, its Affiliates or licensees (other than Sanofi) and their
respective directors, officers, employees and agents in relation to this Agreement. 

  

	15.3	In the event that a Sanofi Indemnitee or an Ascendis Indemnitee, as applicable (hereinafter an “Indemnified Party”) seeks indemnification under this Clause 15, such Indemnified Party shall:
(i) give prompt notice to the indemnifying Party of any such claim, action or demand; (ii) permit the indemnifying Party to assume direction and control of the defence of such claim, action or demand (including decisions regarding its
settlement or other disposition, which may be made in the indemnifying Party’s sole discretion except as otherwise provided herein); (iii) assist the indemnifying Party at the indemnifying Party’s expense in defending such claim,
action or demand; and (iv) not compromise or settle such claim, action or demand without the indemnifying Party’s prior written consent, which shall not be unreasonably withheld or delayed. The Indemnified Party may participate in the
defence of such claim, action or demand through counsel of its choice, but the reasonable cost of such counsel shall be borne solely by the Indemnified Party. Except with the approval of the Indemnified Party, which approval shall not be
unreasonably withheld or delayed, the indemnifying Party shall not enter into any settlement which (i) would result in injunctive or other relief being imposed against an Indemnified Party; or (ii) does not include as an unconditional term
thereof the giving by the claimant to all applicable Indemnified Parties of a release from all liability in respect to such claim or litigation. 

  
 25 

	16.	Limitation of Liability 

  

	16.1	Subject to Clause 16.2, neither of the Parties nor any of their Affiliates shall be liable to each other under any contract, negligence, strict liability or other legal or equitable theory for indirect, incidental,
special, punitive, exemplary or consequential damages arising out of or resulting from this Agreement. The foregoing shall not limit the obligations of either Party from and against Independent Third Party Claims under Clauses 15.1 or 15.2 to the
extent that such Independent Third Party has been awarded such damages. 

  

	16.2	Neither Party limits or excludes its liability for fraud, fraudulent concealment or fraudulent misrepresentation, nor for death or personal injury arising from its negligence. 

 

	17.	Term and Survival 

  

	17.1	This Agreement shall commence with effect from the Effective Date and shall continue until expiration of the Patents unless earlier terminated pursuant to Clause 18. 

 

	17.2	On the expiration or termination of this Agreement each Party shall continue to be bound by the Clauses 2.2 (licence to Ascendis, only in respect of Sanofi Improvements and Joint Improvements that are in existence prior
to expiration or termination), 2.8 (immunity from suit), 10 (confidentiality), 15 (indemnification), 16 (limitation of liability), 17 (term and survival), 19 (effect of termination) and 20 (miscellaneous). 

 

	18.	Termination 

  

	18.1	In the event that Sanofi fails to remit any undisputed sum that it is obligated to pay to Ascendis under Clause 7 and such failure is not made good within thirty (30) Business Days after receipt by Sanofi of a
written notice thereof given by Ascendis, then Ascendis may by written notice terminate this Agreement forthwith. The preceding sentence of this Clause 18.1 shall not apply to any failure of Sanofi to remit the sums which it is obligated to pay
to Ascendis under Clauses 7.1(A) and 7.1(B), and in the event that such sums are not paid to Ascendis within the time periods set out in Clauses 7.1(A) and 7.1(B), Ascendis shall have the right to terminate this Agreement forthwith on
written notice to Sanofi. 

  

	18.2	In the event that either Party commits a material breach of any of the other terms of this Agreement on its part to be performed or observed, the other Party shall have the right to terminate this Agreement by giving
sixty (60) Business Days’ written notice to the defaulting Party; provided however that in the case of a material breach capable of being made good, if the defaulting Party shall make good the said material breach within sixty
(60) Business Days after the notice shall have been given, then the notice shall not be effective. 

  

	18.3	Sanofi may at any time, upon ninety (90) Business Days’ written notice, terminate this Agreement in its entirety, for convenience. 

 

	18.4	If at any time during this Agreement, any Party (the “Challenging Party”) institutes against the other Party a lawsuit or proceeding in a court or before another tribunal of competent jurisdiction in
the nature of a declaratory judgment action of non-infringement, invalidity or unenforceability with respect to any patent licensed to the Challenging Party hereunder, then the other Party shall be entitled to terminate this Agreement forthwith on
written notice to the Challenging Party. 

  
 26 

	19.	Effect of Termination 

  

	19.1	The termination of this Agreement shall be without prejudice to: 

  

	 	(A)	the obligation of Sanofi to pay to Ascendis all milestones achieved prior to termination and other sums accrued, due and payable under Clause 7; and 

 

	 	(B)	any right of, or remedy available to, either Party against the other in respect of anything done or omitted hereunder prior to such termination. 

 

	19.2	If this Agreement is terminated by Ascendis pursuant to Clause 18.1, 18.2 or 18.4, or by Sanofi in its entirety pursuant to Clause 18.3: 

 

	 	(A)	Sanofi shall promptly return, furnish, transfer and/or assign to Ascendis all written Technical Information relating to the Technology Platform which at the date of termination is confidential, without compensation to
Sanofi. For the avoidance of doubt, Ascendis, its Affiliates, licensees and Sub-Licensees shall be entitled to use all such Technical Information and Sanofi, shall, and shall procure that its Affiliates and Sub-Licensees shall immediately cease to
use and thereafter refrain from using such confidential Technical Information. 

  

	 	(B)	All rights of Sanofi hereunder [***] and all licences granted to Sanofi hereunder shall forthwith cease and terminate; 

  

	 	(C)	Sanofi shall and shall procure that its Affiliates and Sub-Licensees shall, cooperate and provide reasonable assistance to Ascendis in obtaining the transfer or grant of any Regulatory Approvals in the Territory for any
Product (other than (i) Glp-1 Product, Glucagon Product, Insulin Product and any combination of Glp-1 Product, Glucagon Product and/or Insulin Product) and (ii) any Product Covered by the Product Patents) to Ascendis or its nominee and
shall ensure that Ascendis is supplied with copies of all relevant reports submitted to the Regulatory Authorities for the purpose of obtaining the transfer or grant of such Regulatory Approvals in the Territory with regard to any such Product in
Diabetes, Diabetes Related Metabolic Disorders and/or Obesity; 

  

	 	(D)	the licences granted by Sanofi to Ascendis pursuant to Clause 2.2 shall survive termination and continue in full force and effect; and 

 

	 	(E)	Sanofi shall pay to Ascendis all justified and documented external costs and expenses that Ascendis and/or its Affiliates incur in the winding down of activities under the Development Plan. 

 

	 	(F)	Subject to Clause 19.4, Ascendis may, at its discretion, [***]. 

  

	19.3	In the case of termination by Sanofi pursuant to Clause 18.2: 

  

	 	(A)	all rights of Ascendis hereunder and all licences granted to Ascendis hereunder shall forthwith cease and terminate; and 

  

	 	(B)	the licence granted by Ascendis to Sanofi pursuant to Clause 2.3 shall survive termination and shall remain in full force and effect. 

 

	19.4	In case of termination by Sanofi pursuant to Clause 18.3 prior to IND Approval of any Product, and if Ascendis notifies Sanofi in writing that it wants to own the Product Patents, Sanofi shall promptly return, furnish,
transfer and/or assign to Ascendis the Product Patents upon payment by Ascendis to Sanofi of [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 27 

	20.	Miscellaneous 

  

	20.1	Further Assurances 

 At any time after the date hereof each of the Parties shall, at the
request and cost of the other Party, execute or procure the execution of such documents and do or procure the doing of such acts and things as the Party so requiring may reasonably require for the purpose of giving to the Party so requiring the full
benefit of all the provisions of this Agreement, subject to any express restrictions in this Agreement on the extent of either Party’s obligations under this Agreement. This includes in particular (without prejudice to the generality of the
foregoing) entry into forms of licence or other instruments confirming such rights for registration with appropriate Intellectual Property Offices, Regulatory Authorities and other authorities in the Territory. 

 

	20.2	Severability 

 In the event that any provision or any part of any provision contained in
this Agreement is declared invalid or unenforceable by the judgment or decree by consent or otherwise of a Court of competent jurisdiction not subject to appeal, all other provisions or parts of provision contained in this Agreement shall remain in
full force and effect and shall not be affected thereby for the term of this Agreement. 
  

	20.3	Assignments 

 Neither this Agreement nor any of the rights and obligations created herein
is assignable or transferable (save for any sub-licence granted in accordance with Clauses 2.2, 2.3 and 2.5) by either Party without the prior written consent of the other, such consent not to be unreasonably withheld or delayed. Notwithstanding the
preceding sentence: 
  

	 	(A)	subject to the provisions of Clause 2.7, Ascendis is entitled to assign this Agreement and/or any rights created herein to, subject to the assumption of the obligations herein by, any purchaser of the whole or a
substantial part of the business of Ascendis. For the avoidance of doubt, the Parties agree that the Technology Platform constitutes a substantial part of the business of Ascendis. 

 

	 	(B)	Sanofi is entitled to assign this Agreement (but not part of this Agreement) to, subject to the assumption of the obligations herein by, any Affiliate or to any purchaser of the whole or a substantial part of the
business of Sanofi, provided that such business includes [***]. 

  

	20.4	Rights cumulative and other matters 

  

	 	(A)	The rights, powers, privileges and remedies provided in this Agreement are cumulative and are not exclusive of any rights, powers, privileges or remedies provided by law or otherwise. 

 

	 	(B)	No failure to exercise nor any delay in exercising by any Party to this Agreement of any right, power, privilege or remedy under this Agreement shall impair or operate as a waiver thereof in whole or in part.

  

	 	(C)	No single or partial exercise of any right, power privilege or remedy under this Agreement shall prevent any further or other exercise thereof or the exercise of any other right, powers, privilege or remedy.

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 28 

	20.5	Costs of Preparation 

 The Parties hereto shall pay their own respective legal costs
incurred in the preparation of this Agreement. 
  

	20.6	Entire Agreement 

  

	 	(A)	This Agreement, together with any documents referred to in it, constitutes the whole agreement between the Parties relating to its subject matter and supersedes and extinguishes any prior drafts, agreements,
undertakings, representations, warranties and arrangements of any nature, whether in writing or oral, relating to such subject matter. 

  

	 	(B)	Each Party acknowledges that it has not been induced to enter into this Agreement by any representation or warranty other than those contained in this Agreement and, having negotiated and freely entered into this
Agreement, agrees that it shall have no remedy in respect of any other such representation or warranty except in the case of fraud. 

  

	 	(C)	No variation of this Agreement shall be effective unless made in writing and signed by each of the Parties. 

  

	20.7	Notices 

  

	 	(A)	Any notice (which term shall in this Clause 20.7 includes any communication) required to be given under this Agreement or in connection with the matters contemplated by it shall, except where otherwise specifically
provided, be in writing in the English language. 

  

	 	(B)	Any such notice shall be addressed as provided in Clause 20.7(C) and may be: 

  

	 	(1)	personally delivered, in which case it shall be deemed to have been given upon delivery at the relevant address if it is delivered not later than 17.00 hours on a Business Day, or, if it is delivered later than 17.00
hours on a Business Day or at any time on a day which is not a Business Day, at 08.00 hours on the next Business Day; or 

  

	 	(2)	sent by pre-paid airmail, or by air courier in which case it shall be deemed to have been given seven (7) Business Days after the date of posting in the case of airmail or two (2) Business Days after delivery
to the courier, in the case of air courier; or 

  

	 	(3)	sent by facsimile, in which case it shall be deemed to have been given when despatched, subject to confirmation of uninterrupted transmission by a transmission report, provided that any notice despatched by facsimile
after 17.00 hours on any Business Day or at any time on a day which is not a Business Day shall be deemed to have been given at 08.00 on the next Business Day; or 

 

	 	(4)	sent by electronic mail, in which case, it shall be deemed to be given when received but subject to the same provisions regarding receipt after 17.00 hours as apply to notices sent by facsimile. 

  
 29 

	 	(C)	The addresses and other details of the Parties referred to in this Clause 20.7(C) are, subject to Clause 20.7(D): 

Ascendis’ Address: 

Ascendis Pharma A/S 
 Tuborg
Boulevard 12 
 DK-2900 Hellerup 

Denmark 
 Fax no: +[***]

 Attention: [***] 

Sanofi’s Address: 

Sanofi-Aventis Deutschland GmbH 

Industriepark Höchst 

65926 Frankfurt am Main 

Germany 
 Fax no: +[***]

 Attention: [***] 
  

	 	(D)	Either Party to this Agreement may notify the other Party of any change to the address or any of the other details specified in Clause 20.7, provided that such notification shall only be effective on the date specified
in such notice or five (5) Business Days after the notice is given, whichever is later. 

  

	20.8	Force Majeure 

  

	 	(A)	Neither Party to this Agreement shall be deemed to be in breach of this Agreement or otherwise liable to the other as a result of any delay or failure in the performance of its obligations under this Agreement if and to
the extent that such delay or failure is caused by Force Majeure and the time for performance of the relevant obligation(s) shall be extended accordingly. The Party concerned shall promptly notify the other Party of the nature and effect of such
event and both Parties shall where the same is practicable use Diligent Efforts to minimise such effect and to comply with the respective obligations herein contained as nearly as may be in their original form, provided that if the Force Majeure
event continues for a period of [***] or more following notification, the Party not affected by the event may terminate this Agreement by giving not less than [***] prior notice to the other Party. 

 

	 	(B)	 For the purposes of Clause 20.8, “Force Majeure” means any circumstances not within the reasonable control of the Party concerned
including, without limitation (i) any strike, lockout or other industrial action, or any shortage of or difficulty in obtaining labour, fuel, raw materials or components; (ii) any destruction, temporary or permanent breakdown, malfunction
or damage of or to any premises, plant, equipment (including computer systems) or materials; (iii) any breach of contract, default or insolvency by or of any Independent Third Party, other than an Affiliate of the Party affected by the force
majeure, or an employee or officer of that Party or Affiliate; (iv) any action taken by a governmental or public authority imposing an embargo, export or import restriction, rationing, quota or other restriction or prohibition; (v) any
civil commotion or disorder, riot, invasion, war, threat of or 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 30 

	 	
preparation for war; or (vi) any accident, fire, or explosion, (other than in each case, one caused by a breach of contract by or assistance of the Party concerned) storm, flood, earthquake,
subsidence, epidemic or other natural physical disaster. Notwithstanding the foregoing, lack of funds, manpower or equipment, interruption or failure of utility service and the fault or misconduct by any personnel engaged by a Party shall not be an
event of Force Majeure. 

  

	20.9	Relationship of the parties 

  

	 	(A)	Nothing in this Agreement shall constitute, or be deemed to constitute, a partnership between the Parties nor, except as expressly provided, shall it constitute, or be deemed to constitute, any Party the agent of any
other Party for any purpose. 

  

	 	(B)	Subject to any express provisions to the contrary in this Agreement, neither Party shall have any right or authority to and shall not do any act, enter into any contract, make any representation, give any warranty,
incur any liability, assume any obligation, whether express or implied, of any kind on behalf of the other Party or bind the other Party in any way. 

  

	 	(C)	Nothing in this Agreement shall oblige either Party to (i) infringe any intellectual property rights or other rights of any person who is not a Party to this Agreement or (ii) do or omit to do anything other
than in accordance with all applicable laws. 

  

	20.10	Counterparts 

 This Agreement may be executed in any number of counterparts, which shall
together constitute one Agreement. Any Party may enter into this Agreement by signing any such counterpart. 
  

	20.11	Third Party Rights 

 Except for Affiliates of the Parties under Clauses 15.1 and 15.2,
who may in their own right enforce the provisions of those Clauses, no person who is not a Party to this Agreement shall have any right to enforce any term of this Agreement. 
  

	20.12	Governing Law and Jurisdiction 

  

	 	(A)	This Agreement and any non-contractual obligations arising from or connected with it shall be governed by German law and this Agreement shall be construed in accordance with German law. 

 

	 	(B)	Subject to Clauses (C) and (D), any dispute arising out of or in connection with this Agreement, including any question regarding the existence, scope, validity, or termination of this Agreement or this Clause, the
legal relationships established by this Agreement or the consequences of its nullity (and including any tortious or statutory claims), shall be referred to and finally resolved by arbitration under the rules of the International Court of Arbitration
of the International Chamber of Commerce (“Rules”), and the Rules are deemed to be incorporated by reference into Clause 20.12(B), save, that notwithstanding anything in the Rules, the Parties preserve their right to appeal or refer
to the German Courts on questions of law. The number of arbitrators shall be three (3), one (1) to be nominated by each Party and the third (the chairman) to be appointed by the International Court of Arbitration. The Parties shall provide
their nominations for arbitrators within thirty (30) days following service of the request for arbitration under the Rules. The place of the arbitration shall be Frankfurt, Germany. The arbitration proceedings shall be conducted in the English
language and any award shall be in English. 

  
 31 

	 	(C)	Each of the Parties agrees that if certain material obligations under this Agreement are not performed in accordance with their specific terms or are otherwise breached, (i) severe and irreparable damage would
occur, and (ii) no adequate remedy at law would exist, and (iii) damages would be difficult to determine. Each of the Parties agrees that, in such case, the injured Party shall be entitled to seek from any court of competent jurisdiction
injunctive relief, whether preliminary or permanent, as well as any other relief permitted by applicable law. 

  

	 	(D)	In respect of any dispute relating to the determination of scope, validity or enforceability of any intellectual property rights, the Parties consent to the exclusive jurisdiction of the courts of the country the laws
of which cause that intellectual property right to come into being and where such courts have jurisdiction the dispute shall be determined according to the laws of that country. 

Signature page follows 

  
 32 

 AS WITNESS the Parties hereof have executed this Agreement the day and year first before written. 

 

									
	Ascendis Pharma A/S	 		 	Sanofi-Aventis Deutschland GmbH
					
	Signed by:	 	 /s/ Jan Møller Mikkelsen
	 		 	Signed by:	 	 /s/ Dr. Martin Siewert

		 	Jan Møller Mikkelsen	 		 		 	Dr. Martin Siewert
		 	President and CEO	 		 		 	Chief Executive Officer
					
	Signed by:	 	 /s/ Michael Wolff Jensen
	 		 	Signed by:	 	 /s/ Dr. Klaus Menken

		 	Michael Wolff Jensen	 		 		 	Dr. Klaus Menken (CFO Germany).
		 	Chairman of the Board of Directors	 		 		 	Chief Financial Officer

  
 33 

 SCHEDULE 1: PATENTS 

Part I: Product Patents 
 Part I:
Product Patent Applications/Patents 
 [***] 

Part II: Technology Platform Patent Applications/Patents 

[***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 34 

 SCHEDULE 2: SHORT FORM PATENT LICENCE 

THIS AGREEMENT is made the [    ] day of [            ] 

BETWEEN: 
  

	(1)	ASCENDIS PHARMA A/S, (“Ascendis”), a company registered in Denmark with its registered office at Tuborg, Boulevard 12, DK-2900 Hellerup, Denmark; and 

 

	(2)	SANOFI AVENTIS DEUTSCHLAND GmbH, (“Sanofi”), a company registered in Germany with its registered office at Industriepark Hoechst 65926 Frankfurt, Germany. 

Ascendis hereby grants to Sanofi an exclusive licence for exploitation, [for all diseases] [in the field of diabetes], of the patent(s) set out in the
Schedule below within [insert relevant country] subject to and terminable in accordance with the terms and conditions of an agreement between the Parties hereto dated
[                    ]. 
 Appendix

 [insert details of relevant patents/patent applications] 

AS WITNESS the Parties have executed this Agreement the day and year first above written. 

 

			
	Signed by	  	)
	For and on behalf of	  	)
	Ascendis Pharma A/S	  	)
		
	Signed by	  	)
	For and on behalf of	  	)
	Sanofi-Aventis Deutschland GmbH	  	)

  
 35 

 SCHEDULE 3: TECHNICAL INFORMATION 

Ascendis Pharma’s TransCon technology encompasses the combination of linkers [***]. The linker families are a diverse group of structures with
inherent chemical self-cleaving properties. Ascendis Pharma ́s transient conjugation allows for a drug compound to be released in the body in a precise, time-controlled fashion, creating a long-acting effect for the original unmodified drug.
Ascendis Pharma ́s TransCon Hydrogel carrier is [***]. 
 The documents in the following list describe the Technical Information that Ascendis
will provide to Sanofi pursuant to Clauses 3.1 and 4.5: 
 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 36 

 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 37 

 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 38 

 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 39 

 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 40 

 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 41 

 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 42 

 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 43 

 SCHEDULE 4: DEVELOPMENT PLAN 

  
 44 

 SCHEDULE 5: LICENCES GRANTED TO ASCENDIS 

None as of the Effective Date. 

  
 45 

 SCHEDULE 6: ASCENDIS EMPLOYEES 

 

	Part I:	Business Team 

 [***] 
  

	Part II:	Individuals subject to non-compete undertakings 

 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 46 

 SCHEDULE 7: LIST OF FILING COUNTRIES 

[***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 47Prepared by R.R. Donnelley Financial -- EX-10.3(a)

 Exhibit 10.3(a) 

[Translation from German] 
 Rental Agreement 
 Technologiepark Heidelberg - Biopark 

3rd Section 

between 

Technologiepark Heidelberg II 
 GmbH & Co. KG 
 Im Neuenheimer Feld 584 

69120 Heidelberg 
 VAT ID no. DE 244 593 546 
 - hereinafter called Lessor - 

and 
 Ascendis
Pharma GmbH (Registered under HRB 337385 with Mannheim local court 
 (Amtsgericht) 

represented by the managing director (Geschäftsführerin) with sole power of 

representation 
 Ms Lotte Sønderbjerg 
 Im Neuenheimer Feld 584 

69120 Heidelberg 
 VAT ID no. DE 813 586 261 
 - hereinafter called Lessee - 

Rented premises 
  

			
	Building:	  	Im Neuenheimer Feld 583-584, 69120 Heidelberg
		
	Floor:	  	 Ground floor (INF 584), 1st floor (INF 583) and
 2nd floor (INF 584),

		
	More specific designation:	  	Partial areas (not entire floor)
		
	More specific description:	  	See para. 3.1

			
	Jan. 30, 2013 09:14	  	 Page
 2
 of 21 of the Rental Agreement

  

 Foundations of Agreement, Condition Precedent 

By virtue of a heritable building right contract with Technologiepark Heidelberg GmbH Lessor holds a subsidiary heritable building right to a property
belonging to the Municipality of Heidelberg, shown outlined in red on the site plans attached as Appendix 1 (complex of buildings 582-584). On this plot of land to which a heritable building right attaches, Lessor has erected a laboratory and
office building for the use of biotechnology companies wishing to pursue scientific research and development or to manufacture products in this context. Together with other building projects marked on the site map, the building is called
“Technologiepark Heidelberg - Biopark, 3rd Section”. 
 Lessor has reached an agreement with Technologiepark Heidelberg GmbH whereby
Technologiepark Heidelberg GmbH must give its consent to the conclusion of rental agreements. 
 The project and intended purpose have been
explained to the Lessee. Plans for the overall project and the rental property were discussed in depth. The Lessee is thus aware of the site, size, and type of use envisaged and also knows about the design and outfit and that to some extent the
buildings and outside facilities are supplied and maintained jointly. 
 Lessor has chosen to subject the rental revenues to turnover tax. The
Agreement is therefore founded on the exercise of an activity that is liable to turnover tax and generates no more than insignificant amounts of tax exempt turnover equivalent to de minimis limits valid at the time. 

Lessee assures that he/she is an entrepreneur within the meaning of the tax regulations. The Lessee shall ensure that the rented property is used only
for turnover that does not preclude the deduction of input tax. The rented property may only be used to generate such levels of tax-exempt turnover, known as the “de minimis” limit, that will not prejudice Lessor’s exercise of the
option under the current tax regulations in their latest revisions (at present 5% pursuant to no. 148 a para. 3 sentence 2 of the Turnover Tax Regulations 2005 (Umsatzsteuerrichtlinie 2005)). 
 The following appendices are attached to the Rental Agreement: 
  

			
	Appendix 1 + 1a	  	Site map and plans of the rental property
		
	Appendix 2	  	Lessee’s declaration of intended purpose dated Nov. 26, 2012
		
	Appendix 2a	  	Excerpt from Lessee’s entry in the Commercial Register of Jan. 2, 2013
		
	Appendix 3	  	Calculation of rented areas and composition pursuant to DIN 277, net internal area (Nettogrundfläche, NGF) pursuant to para. 3.1
		
	Appendix 4	  	Site map, parking spaces
		
	Appendix 5	  	Ordinance on the Distribution of Running costs (BetrKV)
		
	Appendix 6	  	Alteration work
		
	Appendix 7	  	Approval of Technologiepark Heidelberg GmbH dated Dec. 3, 2012
		
	Appendix 8	  	Direct debit authorization
		
	Appendix 9	  	Safety regulations and instructions for using the multi-parking system in the underground car park
		
	Appendix 10	  	Fire regulations
		
	Appendix 11	  	Laboratory equipment provided by Lessor (not applicable)

			
	Jan. 30, 2013 09:14	  	 Page
 3
 of 21 of the Rental Agreement

  

 The rental property is let solely for the purpose described in Appendix 2 on the following terms
and conditions: 
  

	1.	Rental term and termination 

  

	1.1	The tenancy begins on 1st April 2013. The Parties to the Agreement will document the handing-over of the property in the course of a joint tour of inspection.

  

	1.2	When the rental property is handed over a record will be prepared noting its condition and signed by both parties. Any defects existing at this time that do not
seriously hamper the Lessee’s business operations shall be rectified by the Lessor within a reasonable period of time. 

  

	1.3	The Lessor will hand the Lessee the necessary keys or transponders for the property and the rented premises. At own expense Lessee may request the Lessor to supply
additional keys / transponders. A separate record concerning keys will be prepared. 

  

	1.4	The tenancy is firmly agreed until 31 Jan. 2015 (fixed rental term). 

 The lease shall be extended for a period of 24 months unless one Party serves notice of termination no later than 12 months before the expiry of the fixed rental term or the extension period. The notice
to terminate shall be submitted in writing by the legal representative of the Lessee or Lessor. 
  

	1.5	In no cases of termination of the tenancy shall Section 545 BGB (German Civil Code) be applicable, so that the tenancy is not tacitly continued due to lack of
protest. 

  

	1.6	Either Party may cancel the rental of parking spaces by serving notice of one month to the end of the month. The cancellation notice must be submitted in writing by the
legal representative of the Lessee or Lessor. 

  

	1.7	The Parties are aware that delays may arise during the previous tenant’s moving out process. If this should result in a postponed hand-over of the property, the
Lessee may constitute no rights therefrom, in particular this shall not constitute the right to cancel the Rental Agreement or claim damages, provided that the premises are handed over within two months of the hand-over date named in para. 1.1. If
the hand-over cannot be made on the date named in para. 1.1. due to circumstances that are no fault of the Lessor, the start of the rental term shall be delayed for the duration of the hindrance. 

If the Lessor delays the hand-over for more than two months for reasons within his/her control, the Lessee is entitled, while giving
advance warning naming a grace period for performance of at least one month, to claim damages for the time starting at the end of the grace period or to withdraw from the contract. 

			
	Jan. 30, 2013 09:14	  	 Page
 4
 of 21 of the Rental Agreement

  

	2.	Premature ending of the rental period 

  

	2.1	Apart from the legally defined grounds for termination without notice (in particular Sections 543, 569 para. 2 in conjunction with Section 578 para. 2 BGB/German
Civil Code) Lessor is entitled, provided prior written warning with stated grace period for remedy has been delivered, to terminate the tenancy without notice if: 

 

	 	a)	A request to initiate insolvency proceedings against the Lessee has been refused due to lack of assets, if the Lessee ceases to make payments, enters into an out-of-
court settlement procedure, reduces total liable capital or a bill that the Lessee issued is protested. 

  

	 	b)	The Lessee violates the rental purpose as described in Appendix 2 or the obligation to operate despite demands for remedy and fails to immediately desist from the
violation following receipt of Lessor’s reiteration of the complaint sent by registered letter; 

  

	 	c)	The Lessee generates more than merely insignificant turnover tax exempt revenues; 

 

	 	d)	The deposit (security for rent) is not paid within the period allotted; 

  

	 	e)	The Lessee has not furnished the Lessor with evidence at the start of the tenancy or before commencement of activity that insurance has been purchased pursuant to para.
7 sub-para. 7.6 letters a) and b) and pursuant to para. 7 sub-para. 8.1. As far as possible the Lessor will give the Lessee a grace period of 14 days to provide proof of adequate insurance cover prior to terminating the lease. The granting of a
grace period is not a precondition for the effectiveness of notice to terminate the lease. 

  

	2.2	The Lessee shall inform the Lessor immediately if an application to open insolvency proceedings has been filed. 

 

	2.3	If the tenancy is terminated without notice on the part of the Lessor, the Lessee is liable to the Lessor for any losses suffered thereby. The Lessor shall prove that
he/she is striving to limit the losses, e.g. by immediately taking steps to find a new tenant for the property. 

  

	2.4	If the tenancy is terminated without notice by the Lessee for good cause in accordance with legal regulations, the Lessor shall be liable to the Lessee for losses
sustained by termination due to Lessor’s culpability. In this case the Lessee shall prove that he/she has strived to limit the losses, which shall in particular include renting other comparable business premises. 

 

	3.	Rental property 

  

	3.1	The Lessor lets to the Lessee floor space/sections in the building “Im Neuenheimer Feld 583 and 584” as marked in colours in the attached plans (Appendix 1a).
The separate elements are: 

 INF 583, 1st floor, right, storeroom 1.214 

INF 584, basement, compressor room 
 INF 584, ground floor, right 
 INF 584, 2nd floor, left 

			
	Jan. 30, 2013 09:14	  	 Page
 5
 of 21 of the Rental Agreement

  

 The spaces are designated on the plans in accordance with the plans valid at the time
the drawings were made. The present, actual use may differ. The plans do not constitute a guaranteed characteristic. 
 Moreover
the Lessor lets to the Lessee those spaces and sections of the building which the Lessor makes available to several or all of the tenants for their common use, such as e.g. entrance areas, lobby, elevator shafts, elevator lobbies, and staircases.
The rental area is the net internal area (NGF) in accordance with DIN 277 standard, meaning the main and ancillary usable areas, the circulation and functional areas that are reserved exclusively for the Lessee’s use and the measured area of
movable walls and a pro rata share of the circulation, function and usable areas that are in common use. The area taken up by service shafts is not included in the rental area. 
 The communal area is agreed as a flat rate equivalent to 6% of the total of the areas let to individual users. To account for the pro rata share of the communal areas, therefore, the figure for the total
rental area which the Lessee has the exclusive right to use is increased by 6%. 
  

	3.2	The fit-out of the rental property consists of the basic fit-out of the building plus, where appropriate, special structural features (see Appendix 1b) and the
tenant’s additional fixtures and fittings. 

  

	3.3	Prior to commencing any alteration work the Lessee is required to apply to the Lessor for permission. Not all of the laboratory areas and offices in the building have
air- conditioning, so that they can become over-heated on very hot days. This does not constitute a defect in the rental property. The Lessee is obliged to rectify the situation himself if necessary, e.g. with appropriate ventilation.

  

	3.4	For the end-of-tenancy treatment of fixtures that the Lessee has built into the premises see para. 12. 

 

	3.5	Parking spaces 

 The Lessee lets
outside parking spaces no. 33 to 36 and underground garage spaces 3- 6, 11-36, 50-53 and 66 in accordance with Appendix 4 of the Rental Agreement. 
  

	 	•	 	 The Lessee accepts the parking space(s) as seen and recognizes their condition as being in accordance with the Agreement. Constructional or other
alterations to the parking spaces are not permissible. At the end of the rental period the parking spaces are to be returned in clean condition. 

  

	 	•	 	 Sub-letting is not permitted. 

  

	 	•	 	 The Lessor accepts no liability whatsoever, unless he/she has been guilty of gross negligence or wilfulness. 

 

	 	•	 	 The Lessee shall comply with police regulations regarding car parking spaces. 

 

	 	•	 	 Neither fuel nor empty fuel canisters may be stored there. Sounding the horn, loud running of engines and banging car doors, bonnets or boots are
forbidden. 

  

	 	•	 	 Likewise forbidden are washing cars and drawing water from the site. Repairs may not be carried out on site. 

 

	 	•	 	 Cars may not be driven faster than walking pace on the site. Vehicles may not be parked on the site anywhere but on rented car parking spaces.

  

	 	•	 	 The Lessee is responsible for liaising with the janitor with regard to marking the parking spaces (signs roughly the size of an A5 sheet of paper).

 Special conditions pertaining to underground car parking spaces 

			
	Jan. 30, 2013 09:14	  	 Page
 6
 of 21 of the Rental Agreement

  

	 	•	 	 Smoking and the use of naked flames is forbidden in the parking areas and all outbuildings. 

 

	 	•	 	 The brief operating instructions for use of the park lift system 402-170 are an integral part of this Rental Agreement (Appendix 9). The Lessee
undertakes to observe the safety regulations and operating instructions. 

  

	4.	Rent and rent adjustments 

  

	4.1	The monthly rent and advance service charges are composed of the following items: 

 

																							
	 Offices + labs INF 584
	  	 	735.13 m2	  	 				  		  				 				  			
							
	 Ground floor
	  				 				  		  				 				  			
							
	 Offices + labs INF 584,
	  	 	448.40 m2	  	 				  		  				 				  			
	 2nd floor
	  				 				  		  				 				  			
							
	 Plus 6% pro rata share of communal space and areas used by all tenants:
	  	 	71.01 m2	  	 				  		  				 				  			
							
	 Rental area:
	  	 	1,254.54 m2	  	 	 	à	  	  		  	 	13.17	€ 	 	 	=	  	  	 	16,522.29	€ 
							
	 Compressor room INF 584, Basement
	  	 	20.93 m2	  	 	 	à	  	  		  	 	13.17	€ 	 	 	=	  	  	 	275.65	€ 
							
	 Storage space INF 583, 1st floor
	  	 	12.90 m2	  	 	 	à	  	  		  	 	13.17	€ 	 	 	=	  	  	 	169.89	€ 
							
	 Underground parking spaces
	  	 	35	  	 	 	à	  	  		  	 	60.00	€ 	 	 	=	  	  	 	2,100.00	€ 
							
	 Outside parking spaces
	  	 	4	  	 	 	à	  	  		  	 	40.00	€ 	 	 	=	  	  	 	160.00	€ 
		  				 				  		  				 				  			
	 Advance running costs and service charges, currently:
	  	 	1,288.37 m2	  	 	 	à	  	  		  	 	5.09	€ 	 	 	=	  	  	 	6,557.80	€ 
		  				 				  		  				 				  	  
	  
	 
							
	 Subtotal:
	  				 				  		  				 				  	 	25,785.63	€ 
							
	 Value added tax, currently
	  	 	19	% 	 				  		  				 				  	 	4,899.27	€ 
		  				 				  		  				 				  	  
	  
	 
							
	 Total per month
	  				 				  		  				 				  	 	30,684.90	€ 
		  				 				  		  				 				  	  
	  
	 

  

	4.2	Not applicable 

  

	4.3	In addition to the rent a share of the interest on heritable building rights is payable that is proportional to the size of the rental property to the total leasable
area unless the preconditions exist whereby the interest on heritable building rights is reduced to € 0.51 by reason of the subsidiary heritable building rights contract for the present Rental Agreement. A reduction of the interest on heritable
building rights to € 0.51 is granted for a period of fifteen years (starting in 2001) for the structural development of the technology park by means of encouraging start-ups and scientific facilities to move here subject to the proviso that the
premises are let to tenants engaged in scientific research or development and the manufacture of 

			
	Jan. 30, 2013 09:14	  	 Page
 7
 of 21 of the Rental Agreement

  

	 	
products in this context or to tenants who support such purposes or are necessary or useful for the operation of the technology park. The interest on heritable building rights which may be
applicable is EUR 7.39/m2 for the land subject to heritable building rights measuring 11,698 m2 (as at March 2011). 

 The interest on heritable building rights, where applicable, will be billed on a pro rata basis as part of the service charges. 

 

	4.4	The Parties also agree to the following stepped rent provision: 

 With the start of the 2nd rental year the rent for the rental area, storage space and parking spaces will increase by 3% per year in relation to the rent due for the prior year of rental. 

 

	4.5	The rent plus advance payments for running costs and service charges plus value added tax fall due in advance on the 1st workday of each month for that month and are
payable to an account to be named by the Lessor at no charge to the latter. The Lessee authorizes the Lessor to collect the total monthly sum by direct debit in accordance with Appendix 8. 

 

	4.6	If the monthly payment has not been received five calendar days after the date stated above, the Lessor is entitled to invoice the statutory rate of interest pursuant
to Sections 280 para. 2, 286, 288 para. 2 BGB/German Civil Code. The Lessor is entitled to charge a flat-rate fee of EUR 10.00 net per letter of reminder. This does not exclude the possibility of claiming further damages, however, the Lessee is at
liberty to prove that losses sustained were lower than claimed. 

  

	4.7	The Lessee may offset counter-claims against the rent only if there is no dispute about such with the Lessor or a court of law has issued its final ruling on said
claims. In all other cases it is not permissible to offset amounts or claim a right of retention. 

 The Lessee
agrees that the rent due may be assigned to a third party, e.g. the refinancing bank. 
  

	5.	Running costs and service charges 

  

	5.1	The Lessee shall pay all running costs and service charges for the rental property and a pro rata share (para. 5.3) of such costs for the building “Im Neuenheimer
Feld 582- 584”, the entire site and the shared facilities in the Technology Park - Biopark (3rd Section) pursuant to the Ordinance on the Distribution of Running Costs attached as Appendix 5: 

 

	 	1)	ongoing public encumbrances on the real estate, specifically the property tax; 

 

	 	2)	the costs of water supplies, 

  

	 	i)	which include the costs of water consumption, base fees, costs of renting or otherwise obtaining the use of water meters, the costs of using them, including the costs
of calibration, preparing accounts and allocating charges, the costs of servicing water flow regulators, the costs of operating an in-house water supply facility and a water purification plant including the purifying materials;

			
	Jan. 30, 2013 09:14	  	 Page
 8
 of 21 of the Rental Agreement

  

	 	3)	the costs of drainage, 

  

	 	i)	which include charges for draining the building and land, the costs of operating an appropriate non-public plant and the costs of operating a drainage pump;

  

	 	4)	the costs 

  

	 	a)	of running the central heating plant plus the flue gas plant, which include the costs of fuels used and their delivery, the costs of electricity to operate the system,
costs of attending to, monitoring and servicing the plant, regular inspection to ensure the plant is in working order and safe to operate including adjustments by a qualified worker, cleaning the plant and the service room, the costs of having
measurements taken in compliance with the German Federal Act on Control of Emissions (Bundes-Immissionsschutzgesetz), the costs of renting or otherwise obtaining the use of equipment to record consumption and the costs of using equipment to record
consumption including the costs of calibration, preparing accounts and allocating charges 

  

	 	i)	or 

  

	 	b)	of operating the central fuel supply plant, 

  

	 	i)	which includes the costs of fuel consumption and delivery, the costs of electricity to operate the system, the costs of monitoring the plant, the costs of cleaning the
plant and service room 

  

	 	ii)	or 

  

	 	c)	the independent commercial supply of heating, including from plants as contemplated in letter a 

 

	 	i)	which includes payment for the supply of heating and the costs of operating the house facilities which belong to the system in accordance with letter a

  

	 	ii)	or 

  

	 	d)	cleaning and servicing heating systems that serve one individual floor and single gas burners 

 

	 	i)	which includes the costs of removing water deposits and combustion residues in the plant, the costs of regular inspections to check that the plant is in working order
and safe to operate and, in this connection, hiring a qualified worker to adjust any settings and the costs of taking measurements in compliance with the German Federal Act on Control of Emissions (Bundes-Immissionsschutzgesetz);

  

	 	5)	the costs 

  

	 	a)	of operating the central plant for the supply of hot water, 

  

	 	i)	which includes the costs of supplying water in accordance with no. 2, unless already included and the costs of heating water in accordance with no. 4 letter a

  

	 	ii)	or 

  

	 	b)	the independent commercial supply of hot water, including from plants as contemplated in letter a 

 

	 	i)	which includes payment for the supply of hot water and the costs of operating the house facilities which belong to the system in accordance with no. 4 letter a

			
	Jan. 30, 2013 09:14	  	 Page
 9
 of 21 of the Rental Agreement

  

	 	ii)	or 

  

	 	c)	cleaning and servicing hot water devices, 

  

	 	i)	which includes the costs of removing water deposits and combustion residues inside the devices and the costs of regular inspections to check that they are in working
order and safe to operate and, in this connection, hiring a qualified worker to adjust any settings; 

  

	 	6)	the costs of integrated heating and hot water plants 

 a) in connection with central heating plants as described in no. 4 letter a and in accordance with no. 2 unless already included therein, 

 

	 	i)	or 

 b) in connection with the
independent commercial supply of heating as described in no. 4 letter c and in accordance with no. 2 unless already included therein, 
  

	 	i)	or 

 c) in connection with
integrated plants to supply individual floors with heat and hot water as described in no. 4 letter d and in accordance with no. 2 unless already included therein; 
  

	 	7)	the costs of operating elevators and service lifts, 

  

	 	i)	which include the costs of electricity to operate them, the costs of supervising, attending to, monitoring and servicing the lifts, regular inspections to check they
are in working order and safe to use, including any necessary adjustments by qualified workers and cleaning the lifts; 

  

	 	8)	the costs of street cleaning and waste removal; street cleaning costs include the charges levied for public cleaning services and the costs of any relevant non- public
services; the costs of waste removal specifically include the charges levied for the provision of waste collection services, the costs of any relevant non- public services, the operating costs of the waste compactors, waste chutes and pneumatic
refuse collectors and the costs of refuse recording systems including the costs of preparing accounts and allocating expenses; 

  

	 	9)	the costs of cleaning and pest control 

  

	 	i)	cleaning the building includes the costs of cleaning the parts of the building used by all tenants, such as entranceways, corridors, stairs, cellars, attic spaces,
laundry rooms, the elevator cabins; 

  

	 	10)	the costs of looking after the gardens 

  

	 	i)	these include the costs of tending to the areas laid out as gardens, including planting new plants and shrubs if necessary, care of playgrounds including the renewal of
sand and looking after squares, entranceways and driveways that are not open to public traffic; 

  

	 	11)	the costs of lighting 

  

	 	i)	these include costs of electricity for the outside lights and lighting in the parts of the building used by all tenants, such as entranceways, corridors, stairs,
cellars, attic spaces, and laundry rooms; 

  

	 	12)	the costs of chimney sweeping, 

			
	Jan. 30, 2013 09:14	  	 Page
 10
 of 21 of the Rental Agreement

  

	 	i)	these include the fees for sweeping as laid down in the schedule of fees for the region unless not already treated as costs in connection with no. 4 letter a;

  

	 	13)	the costs of property and liability insurance 

  

	 	i)	these specifically include costs for insuring the building against fire, storm & tempest, flood and other natural hazards, glass insurance, liability insurance for
the building, the oil tank and the lifts; 

  

	 	14)	the costs of janitor services 

  

	 	i)	these include the wages, social insurance contributions and all cash- equivalent benefits which the janitor receives for his services from the owner or holder of the
heritable building rights which do not relate to maintenance, repair, renewal, redecoration work or administration of the building; whenever the janitor has performed certain tasks, the costs for his work may not be billed as costs pursuant to nos.
2 to 10 and 16; 

  

	 	15)	the costs 

  

	 	a)	of operating the joint antenna installation, 

  

	 	i)	these include the costs of electricity to operate the system and costs of regular inspections to check it is in working order, including any adjustments required by a
qualified worker or the fees for the use of an antenna installation that does not belong to the building and the fees which arise under copyright law for the onward transmission of cable broadcasts, 

 

	 	ii)	or 

  

	 	b)	of operating a private distribution system linked to a broadband cable network i) this includes the costs corresponding with letter a, plus the regular monthly base
fees for the broadband cable connections; 

  

	 	16)	the costs of operating the laundry facilities 

  

	 	i)	this includes the costs of electricity to operate the facilities, the costs of supervising, servicing and cleaning the facilities, regular inspections to check they are
in working order and safe to operate and the costs of water supplies in accordance with no. 2 unless they have already been included therein; 

  

	 	17)	other running costs 

			
	Jan. 30, 2013 09:14	  	 Page
 11
 of 21 of the Rental Agreement

  

 Furthermore, the Lessee shall bear a pro rata share of the costs for: 

 

	 	18.	Ventilation and air-conditioning systems, 

  

	 	19.	General electricity use, 

  

	 	20.	Power consumption in the rental property unless the Lessee has concluded an agreement pursuant to para. 5.2 in his/her own name and for own account.

  

	 	21.	Cleaning the façade and 

  

	 	22.	The costs of permanent surveillance. The Lessor will only hire the services of a security firm if he/she thinks it necessary due to specific events in the locality.

  

	 	23.	The costs of security services including the necessary expenses for rooms and other costs incurred in this connection and 

 

	 	24.	The pro rata costs for the commercial (about €4/m2 p.a.) and technical management services rendered by the property management companies hired for the purpose
and maintenance costs according to the more specific details in para. 6.1 

  

	 	25.	Interest on heritable building rights (see para. 4.3) 

  

	 	26.	Costs of complying with the duty to ensure safe access 

  

	 	27.	Cost of extended coverage insurance for the building and 

  

	 	28.	The costs of insurance against loss of rental income and 

  

	 	29.	Remaining costs for the janitor not covered in no. 14 of the Ordinance on the Distribution of Running Costs (see Appendix 5). 

 

	5.2	The Lessee shall as far as possible conclude contracts for the supply of electricity and telephone services etc. in the rooms Lessee uses exclusively in his/her own
name and for own account. The other running costs and service charges will be allocated as shown in para. 5.3. 

  

	5.3	The key whereby previously named running costs and service charges are allocated to individual tenants is based, with regard to hot water and heating, on the Heating
Costs Ordinance (where technically feasible). Otherwise tenants will pay a share of running costs and service charges reflecting the size of their rental space in proportion to the entire leasable area. 

If running costs and service charges relate solely to the Lessee or the Lessee as part of a group of tenants in the building or in one or
several of the buildings in the 1st to 3rd section of the Technology Park, these costs will be paid by the Lessee alone or as a pro rata share in proportion to the space rented by the tenants concerned. At his/her discretion the Lessor is entitled
to use other cost calculating methods if there are objective reasons for the change. The key for the allocation of hot water and heating costs is excepted from this rule as allocation is based on the Heating Costs Ordinance. However, the costs for
e.g. looking after and maintaining all the outside areas and the fountains on the site and for ensuring safe access may initially be allocated by gross volume (Bruttorauminhalt, BRI) of the separate buildings and then allocated pro rata to the
individual tenants. To determine running costs and service charges, consumption will be metered and the costs allocated by the company hired for the purpose in accordance with normal procedures for determining consumption and preparing accounts.

 If new public levies are introduced or if new costs directly or indirectly attributable to the management of the rental
property arise, the Lessor may bill the Lessee for these costs from the time they arise in accordance with the provisions of this Agreement only 

			
	Jan. 30, 2013 09:14	  	 Page
 12
 of 21 of the Rental Agreement

  

 
if the Lessor was unable to predict and avoid the emergence of the new costs. The sum payable by the Lessee for these new costs is limited to 10% of the running costs and service charges agreed
in this Contract. 
  

	5.4	As agreed in para. 4.1 the Lessee shall pay an advance sum in respect of running costs, service charges and maintenance costs as per para. 6.1. For the first year of
tenancy these service charges are an estimate. The Lessor is entitled to adjust this figure once a year at his/her discretion to reflect the actual expenditure. The Lessor shall inform the Lessee of the reasons for the increase.

  

	5.5	Final accounts will be prepared by the Lessor or a company hired by Lessor covering the period of one calendar year and these should be presented by the 31st Oct. of
the following year. Any credits/debits arising from the accounts are to be settled within 4 weeks of the invoice date. 

  

	5.6	The accounts shall be deemed accepted if the Lessee lodges no objection within two months of receipt and if the Lessor has given notice of this legal consequence in the
statement of account. 

  

	5.7	There will be no preparation of interim accounts. If the Lessee moves out before the end of an accounting period, costs, including consumption costs for the period of
occupancy as a pro rata temporis share of the annual total and total accounting charges will be charged. On moving out, the Lessee pays the fees for any change of user. 

 

	5.8	The Lessor is also entitled to transfer the collection of individual charges, such as e.g. electricity costs, directly to the utility concerned.

  

	5.9	Running costs and service charges are to be paid by the Lessee irrespective of whether and to what extent Lessee uses the shared facilities. 

 

	6.	Maintenance/repair of the rental property 

  

	6.1	The Lessor is responsible for maintenance, repairs and servicing of the rental property. With the Lessor’s consent the Lessee is entitled, and if the Lessor so
demands, obliged, to order and pay for the repair of any damage caused by tenancy (wear and tear, damage by the Lessee or one of his/her vicarious agents). 

 For purposes of preparing the service charge accounts the Lessee bears the costs of maintenance, repairs and servicing for the interior of the rental property and a pro rata share of these costs in
relation to the spaces and objects designated for communal use of tenants, up to a maximum amount of 10% of the annual net rent ex service charges (pro rata temporis) only to the extent that these are caused by tenants’ usage and to the extent
that these costs are not to be paid by the Lessor pursuant to para. 6.2. The non- let areas are treated like let areas. The pro rata share attributable to non-let areas cannot be prorated to the let areas. 

			
	Jan. 30, 2013 09:14	  	 Page
 13
 of 21 of the Rental Agreement

  

	6.2	The Lessor pays the costs of maintenance, repairs and servicing for: 

  

	 	a)	the roof of the building 

  

	 	b)	the structural elements of the rental property and the building, such as outer walls, load-bearing interior walls, supports and foundations 

 

	 	c)	the façade, with the exception of the windows and the window fittings, blinds and shutters, all outer doors (including roller grilles), entrance gates,
façade cleaning etc. 

  

	 	d)	elements outside the rental property. 

  

	6.3	To the extent that the Lessor has claims against those involved in the construction of the rental property in respect of defects or claims against insurance companies,
the Lessor is obliged to prioritize the furtherance of these claims. 

  

	7.	Insurance and liability 

  

	7.1	The Lessee is liable for all damage arising from culpable violation of his/her duties to act with care. Lessee is also liable within the meaning of Section 278 of
the German Civil Code/BGB for all culpable damage caused by employees, visitors, suppliers, tradesmen, sub-tenants and similar people. 

  

	7.2	The Lessee bears the burden of proof that he/she has not caused and is not to blame for the damage, inasmuch as the damage is a result of use of the rented property.

  

	7.3	The Lessee shall furthermore reimburse the Lessor for any losses arising from a violation of the duties detailed in the preamble relating to the option to charge
turnover tax, in particular the duties described in Section 9 para. 2 of the German Turnover Tax Law (Umsatzsteuergesetz). 

  

	7.4	The rental property consists of space within a technology park. If and as far as the Lessee intends to handle the kind of substances, in particular chemicals and
radioactive materials, or operate or install the type of technical plant that could endanger the rental property, people’s health or the environment or cause nuisance to third parties, it is his/her duty to comply with all the relevant
regulations; the Lessee shall particularly ensure that water-polluting substances are not discharged with the waste water except in accordance with limits imposed by Water Law or permitted by the appropriate authorities. Evidence of compliance with
regulations is to be supplied to the Lessor. Lessee is obliged to give the Lessor written explanations of risks and to indemnify Lessor from all claims from third parties or authorities. These aforesaid provisions shall apply in like manner to any
substance that was originally deemed harmless and is later found to be hazardous. The Lessee is also obliged to purchase insurance for these risks and to cover his/her liability and to present proof thereof to the Lessor at the start of the tenancy.

  

	7.5	The Lessee is responsible for ensuring safe access to his/her rental property. The Lessee therefore indemnifies the Lessor against all claims from third parties,
including own claims. The Lessee shall position the requisite fire extinguishers in the rental property and ensure their ongoing maintenance. In respect of the spaces communally used by all the tenants at the technology park, the Lessor is
responsible for ensuring safe access and allocates the costs for this duty in accordance with para. 5.3. 

			
	Jan. 30, 2013 09:14	  	 Page
 14
 of 21 of the Rental Agreement

  

	7.6	If parts or all of the rental property cannot be used for reasons that are no fault of the Lessee, he/she shall be excused from paying rent for the period during which
use is not possible; if it is partially impossible to use the property, the Lessee shall be obliged to pay only a correspondingly reduced rent. 

 However, the rent may be reduced only if considerable impairment to the suitability for use of the rental property exists, if the Lessor has been set a reasonable period of time in which to remedy the
situation and if the claim for a rent reduction has been acknowledged by at least one expert who has been approved by both parties or if the reason for reducing the rent and the size of the reduction have been determined and are undisputed.

 The claim for rent reduction may be asserted only after presentation of an expert opinion, exists however for the
entire period of impairment from its start until its remedy. The losing party shall pay the costs of the expert opinion. //entire paragraph deleted, signature by Lotte Sønderbjerg from April 11, 2013;
second, illegible, signature from April 15, 2013// 
  

	7.7	The Lessee may only bring claims against the Lessor for defects in the rental object if they are the result of culpable violation of a material obligation under the
Agreement, otherwise of a wilful or grossly negligent violation of the Agreement on the part of the Lessor or his vicarious agents or derive from the lack of a guaranteed agreement as to the characteristics of the rental property. This limitation of
liability does not extend to damage caused by the Lessor’s violation of duties if they cause injury to life, limb or health. Everyone acting on behalf of the Lessor who comes into contact with the rental property is considered his vicarious
agent within the meaning of this clause. 

 The Lessor is, moreover, liable to the limit of what an insurer will
pay in recompense for the loss or to what may be successfully claimed from some other third party. 
 The Lessor is not liable:

  

	 	a)	for the suitability of the rental property for the Lessee’s specific use and requirements. It is the Lessee’s task to examine whether the fit-out of the
building is suited for his/her specific purposes. The Lessee shall obtain the separate operating licence (Betriebsbaugenehmigung) at his/her own expense and present this to the Lessor at the start of the tenancy. This shall apply likewise to all
other requisite permits, e.g. those required by the German law on genetic engineering (Gentechnikgesetz) and the German Federal law on infectious diseases (Bundesseuchengesetz) plus, if necessary, any agreements with the Trade Supervisory Office
(Gewerbeaufsichtsamt), the Health Department (Gesundheitsamt), etc. 

  

	 	b)	for the supply of energy, electricity, water, district heating, district cooling, gas, etc. by the utilities or for the breakdown of the heating or cooling systems,
unless he/she is responsible for the breakdown. It is the Lessee’s responsibility, especially when conducting trials and experiments, to take precautions against a temporary malfunction or breakdown of utility supplies. The Lessee is obliged to
purchase insurance against the risks arising from malfunctions/breakdowns of utility supplies to the extent that they can be insured. The Lessee is moreover obliged to notify the Lessor of the danger of especially large damage.

			
	Jan. 30, 2013 09:14	  	 Page
 15
 of 21 of the Rental Agreement

  

	 	c)	for the endurance of the driveway, delivery road and other traffic routes to the rental object or the extent to which they can be used if and as far as any limitations
result from official measures for which the Lessor is not responsible, or that access to the rental object is guaranteed at all, or for impairment to the usefulness of the rental property due to activities on neighbouring sites, such as construction
work. 

  

	7.8.	The Lessee shall purchase and maintain extant for the duration of the tenancy insurance cover for the following items and on request furnish evidence of cover to the
Lessor: 

  

	 	a)	Liability/business liability for an adequate sum, which must insure against all risks deriving from the Lessee’s business operations pursuant to 7.4. of the Rental
Agreement. 

  

	 	b)	Insurance for objects brought into the rented property including a vandalism clause 

 

	 	c)	Insurance against business interruption 

  

	 	d)	Insurance for lost keys 

  

	 	e)	Insurance against environmental pollution and liability insurance for radiation to cover possible harm from waste water or radiation. 

If the Lessee does not purchase the insurance cover named above, the Lessor is not liable for any losses that would have been covered by
these insurance policies. Para. 2 sub-para. 2.1. letter e) is not thereby affected. 
 The Lessor will purchase the following
insurance policies, whereby the premiums will be allocated pursuant to para. 5: 
  

	 	a)	Building insurance against fire, mains water, sprinkler leaks and storm & tempest, including insurance against loss of rental income 

 

	 	b)	Liability insurance for the owners of real estate and land 

  

	 	c)	Liability insurance for environmental pollution 

  

	 	d)	Glass breakage 

  

	 	e)	Insurance against damage due to civil unrest, wilful or malicious damage and strikes, inasmuch as it is possible to insure against these events.

  

	8.	Obligation to operate, use of the rental property, sub-letting, protection from competition 

 

	8.1	The Lessee shall conduct business in the rented property pursuant to the terms of the Agreement, in particular in compliance with the rental purpose as stated in
Appendix 2 and shall treat the rented property and other facilities with care and consideration. Alterations to the purpose for which the premises are used will always require prior written consent of the Lessor and, if appropriate, of the
Technologiepark Heidelberg GmbH. 

  

	8.2	 When using the property, the Lessee shall act with consideration towards other tenants, whereby there shall be no impairment to the use of the rented
property in accordance with the terms of the Agreement. Specifically, the Lessee shall take care that his/her 

			
	Jan. 30, 2013 09:14	  	 Page
 16
 of 21 of the Rental Agreement

  

	 	
use of machinery, equipment and materials or substances causes no nuisance or disturbance to other tenants. If there is no efficient protection from adverse effects the Lessor has the right to
demand the removal of the plant. The Lessee shall indemnify the Lessor against any claims brought by other tenants due to nuisance. 

 If third parties cause nuisance, Lessor is obliged, if the Lessee so desires, to assign to the Lessee his/her claims against the originator of the nuisance. If this should not be legally admissible, the
Lessor will authorize the Lessee to claim the rights on behalf of the Lessor. 
  

	8.3	Prior written consent from the Lessor and the Technologiepark Heidelberg GmbH will be required if rooms are to be sub-let and may be refused only for good cause. Good
causes are, for example, use of the rental premises for other purposes than those demanded in para. 4.3 in order to qualify for the reduced interest on heritable building rights, or sub-letting to companies that are not start-ups so that the grounds
for rent reduction as described in para. 4.2 are not given, likewise letting rooms at a higher rate than agreed in this Contract, unless the higher rent is charged because the Lessee offers additional benefits to their sub-tenant (e.g. additional
services or fit-out). 

  

	8.4	In cases of sub-letting to third parties or permitting third parties to use the premises the Lessee herewith assigns to Lessor all claims he/she has against sub-tenants
or third parties, in particular claims for payment of rent and compensation for non-performance as security for all Lessor’s claims under the terms of this Agreement. The Lessor accepts this assignment. With regard to the internal relationship
between the parties, the Lessee remains authorized to collect the assigned claims in his/her own name. The Lessor is entitled to revoke this authority if the Lessee falls behind in the fulfilment of contractual duties under this Rental Agreement -
in particular payment obligations. 

  

	8.5	The Lessor offers no protection from competition. 

  

	9.	Building alterations during the term of the tenancy 

  

	9.1	The Lessor must give written consent to any building alterations. Permission may be denied only for good cause. 

The Lessee shall bear the costs of building alterations. 
 It is the Lessee’s task to apply and pay for official permits. Lessee shall present building plans to Lessor for the latter’s decision, and as soon as building work has been completed shall make
the as-built drawings etc. available to the Lessor. 
 The Lessee bears all hazards and risks in connection with the building
work he/she has ordered. 
 If the building alterations should result in a higher basis for the assessment of land tax and an
increase in premiums for insurance policies purchased by the Lessor, the Lessee shall reimburse the Lessor for the extra amount. 

			
	Jan. 30, 2013 09:14	  	 Page
 17
 of 21 of the Rental Agreement

  

	9.2	If, after the property has been handed over, the Lessee receives notice from the authorities of official regulations or requirements in connection with the intended
purpose as stated in Appendix 2, the costs thereof shall be paid by the Lessee. 

  

	9.3	When the tenancy has ended - for whatsoever reason - the Lessee shall pay to have the premises returned to the condition in which they were prior to building
alterations, if the Lessor so requires, unless the Lessor is prepared to accept the alterations or the parties signed a written agreement stating otherwise at the time the Lessor consented to the building alterations. 

If the Lessor takes the premises back in their altered state, the Lessee is not entitled to any compensation unless otherwise agreed.

  

	10.	Advertising 

  

	10.1	Spaces are available at designated parts of the rental property where the Lessee may display his/her nameplate. The Lessee shall pay for the production and mounting of
the nameplates. The type and number of plates is determined solely by the Lessor in agreement with the Technologiepark Heidelberg GmbH. 

  

	10.2	At the end of the rental period or whenever necessary for maintenance work, the Lessee shall remove the nameplates at his/her own expense and return the spaces to their
original condition. 

  

	11.	Lessor’s access to the rental property 

  

	11.1	The Lessor or people he/she has authorized may enter the rented property during normal business hours in consultation with the Lessee. 

 

	11.2	If the Lessor wishes to sell or let the rental property, Lessor or his/her authorized representatives may show potential clients around the rental property on the terms
stated in 11.1. 

  

	11.3	The Lessor or his/her authorized representatives are entitled to enter the rental property without making an appointment with the Lessee in situations of acute danger.
The Lessee shall ensure that if own locking systems are installed, the Lessor or his/her authorized representative is able to enter the premises if there is imminent danger. 

 

	12.	Termination of the lease 

  

	12.1	At the end of the lease the Lessee shall return the rental property to the Lessor in professionally renovated condition, unless this requirement may be ignored because
the property is in good condition due to previous renovation work. 

 Apart from that, all damage within the rental
property that is above and beyond wear and tear through normal use must be repaired and all keys and transponders handed back to the Lessor. Any appurtenances and fittings that the Lessor may have allowed the Lessee to use must be cleaned,
decontaminated and returned in usable condition. 

			
	Jan. 30, 2013 09:14	  	 Page
 18
 of 21 of the Rental Agreement

  

 Plant and equipment the Lessee has installed for his/her business operation must,
subject to the following paragraph, be removed at the end of the tenancy and any damage caused by fitting and removal repaired. If operating equipment is left inside the rental property no compensation shall be owed unless the Parties have reached a
written agreement to the contrary. The Lessor permits the Lessee to negotiate with incoming tenants on the take-over of operating equipment and to sell or transfer the equipment. However, this must not lead to a delay in concluding a new rental
agreement. 
 Special building fit-out work and fittings built in by the Lessee which become a material part of the building
shall remain in the building when the lease ends. If these constitute a lasting economic benefit for re-letting the premises, compensation will be paid for these fittings at their remaining economic value. The economic value is calculated as the
value that the fittings would have if removed from the rental property less the cost of dismantling. If no economic benefit remains in terms of re-letting, the Parties assume that these fitting have been used up and are of no value. In this case the
Lessor can demand that fittings be removed and the rental property restored to its original condition at the Lessee’s expense. Building alterations are also subject to the provisions of para. 9.3. 

 

	12.2	The last day of the rental period is the day scheduled for hand-over. 

  

	12.3	At the end of the tenancy, the Parties will reach agreement on whether all the work detailed in para. 12.1 needs to be done or whether to set a one-off payment for
these tasks. If the Parties fail to agree on a specific one-off payment, the Lessee is obliged to have the work done pursuant to para. 12.1 and to continue to pay the rent plus service charges or compensation for further use up to the end of the
month in which the due and proper surrender of the property occurs. If the Lessor should receive rent revenues for the rental property during this period, these will be offset. This shall in no way affect further claims of the Lessor, in particular
claims for a larger amount of compensation, nor the Lessee’s right to prove that the loss suffered is actually lower. 

  

	12.4	If, contrary to the terms of the Agreement, the Lessee leaves objects in the rental property at the end of the tenancy, the Lessor is entitled to remove them from the
property at Lessee’s expense having first made written complaint with the naming of a period for performance. The Lessor has no obligation to keep the objects safe. Any claims the Lessor may have due to the delayed surrender of the rental
property are not thereby affected. 

  

	12.5	No later than three months prior to the end of the rental period the Lessor is entitled to affix to the outside windows notices advertising that the property is to let.

  

	12.6	If the Lessee moves out prematurely, the Lessor shall have the right to have other maintenance or alteration work carried out in the rental property without the Lessee
construing therefrom claims for a credit on the rent or similar. 

			
	Jan. 30, 2013 09:14	  	 Page
 19
 of 21 of the Rental Agreement

  

	12.7	Inasmuch as the possibility exists that the Lessee may work with environmentally hazardous substances which may lead to contamination, the Lessee is obliged at the end
of the Rental Agreement to allow an expert to examine the property at Lessee’s expense for evidence of pollution. If necessary, the Lessee will clean up pollution in accordance with the relevant regulations at his/her own expense and prove
he/she has done so by means of an expert opinion he/she has commissioned at own expense. This obligation shall exist even if the pollution has arisen during the use of the rental property in accordance with the agreed purpose.

  

	13.	Deposit 

  

	13.1	As security for all claims the Lessor has against the Lessee under the terms of this Agreement, the Lessee undertakes to pay Lessor a deposit of 3 gross monthly rents
(total as shown in para. 4.1 of this Agreement, rounded down) in other words € 90,000.00 prior to fitting the Lessee’s specific equipment into the premises and no later than commencement of the rental period pursuant to para.
1.1 of this Agreement. When the rent rises in accordance with para. 4 the Lessee shall pay the resulting difference. The Lessor will pay the deposit money into a separate savings account held at a bank earning the usual rate of interest for deposits
with 3 months’ withdrawal notice. 

  

	13.2	The Lessor is entitled to use this deposit to satisfy demands that have fallen due. In such instances, the Lessee is obliged to repay the necessary amount immediately
and thus return the deposit to its original figure. The Lessee is not permitted to offset amounts due to the Lessor against his/her claims to repayment of the deposit prior to the date when repayment falls due as described in 13.3. (“running
down” the deposit). 

  

	13.3	When the rental property has been surrendered the Lessor shall present accounts for the deposit money and return the remaining deposit total including interest to the
Lessee. The Lessee’s claim for repayment falls due when he/she receives the statement of accounts, but no later than six months after the surrender of the rental property. For the service charges which are billed in accordance with para. 5 of
this Agreement, part of the deposit amounting to one monthly rent may be retained until these accounts have been prepared, and held up to but no longer than the date on which service charges and/or subsequent credits or debits for final settlement
of service charges fall due. 

  

	14.	Other matters 

  

	14.1	The Lessor is entitled to transfer all rights and duties under this Agreement to a third party. 

 

	14.2	Inasmuch as obligations under this Agreement are not transferred by operation of law to the legal successor of each Party, each Party to the Agreement undertakes to
enjoin possible legal successors to assume the obligations. 

  

	14.3	If the rental property is sold the Lessor will ensure that the purchaser fulfils the obligations constituted by this Agreement. The Lessor is, however, released from
liability pursuant to Section 566 a sentence 2 of the German Civil Code/BGB if he/she returns the deposit on the sale of the property or if the Lessor transfers the deposit to the purchaser in discharge of obligations and the Lessee agrees
thereto. 

			
	Jan. 30, 2013 09:14	  	 Page
 20
 of 21 of the Rental Agreement

  

	14.4	If the rental property is sold the Lessor is entitled to submit to Lessee a statement of Rental Agreement documents and request the latter to furnish a declaration of
completeness. The Lessee is obliged to inform the Lessor in writing within 14 days whether the statement is complete. If the Lessee submits a declaration of completeness or fails to notify the Lessor of mistakes or omissions within 14 days, Lessee
may not subsequently plead agreements which were not listed in the Lessor’s statement, provided that the request included a note pointing out this legal consequence. 

 

	14.5	The Lessee shall inform the Lessor immediately of any change in Lessee’s legal form, and any other major alteration in the Commercial Register or in the
application to register (such as e.g. changes in capital, the purpose of the company, the general managers or board of directors); Lessee shall likewise inform of the sale of the entire business or major parts thereof to third parties or of changes
in the shareholder structure. 

  

	15.	Final provisions 

  

	15.1	This Rental Agreement may only be amended or altered in writing. No ancillary oral agreements have been made. 

 

	15.2	Within the meaning of this Agreement “authorities” are all institutions or individual people taking action in connection with the rental property by virtue of
a law, an ordinance, decree or similar regulations (e.g. TÜV technical supervision, VdS security inspection, the Trade Supervisory Office (Gewerbeaufsichtsamt), Health Department (Gesundheitsamt), etc.) 

 

	15.3	If individual provisions of this Agreement should be invalid or inoperable, or should there be omissions in the text, this shall in no way affect the validity of the
remainder of the provisions. To replace the invalid or inoperable provision the Parties will agree on a valid provision to correspond with the meaning and purpose of the invalid provision. Should there be an omission in the Agreement the Parties
will agree to a provision corresponding with the one which it is reasonable to assume that, in view of the meaning and purpose of the Agreement, the Parties would have included, if this point had been considered at the outset.

  

	15.4	The contracting Parties are aware of the special legal requirements for written form as contained in Sections 550, 126 of the German Civil Code/BGB. They hereby
mutually undertake whenever one Party requests, to perform all actions and submit all declarations necessary in order to comply with the legal requirement for written form and not to prematurely terminate this Agreement by invoking non-compliance
with the legal requirement for written form. The aforesaid shall apply not only to the conclusion of the original/main Agreement, but also to agreements constituting addenda, amendments and supplements. 

 

	15.5	This Rental Agreement - including any excerpts therefrom - may not be published, nor may third parties be granted access to it or information regarding it without the
consent of the Lessor (Section 1.11 German Copyright Law/UrhG, Section 823 ff German Civil Code/BGB). 

			
	Jan. 30, 2013 09:14	  	 Page
 21
 of 21 of the Rental Agreement

  

	16.	Special Agreements 

  

	 	•	 	 The Lessee is aware that he/she must personally obtain at his/her own expense any permits under (public) law and official licences for the activities
named in the declaration of purpose (Appendix 2). If a permit is refused, this shall not entitle the Lessee to claim damages from the Lessor. 

  

	 	•	 	 The Lessee will order, pay for and bear the risks of maintenance and repair of the facilities inside the rental property (e.g. digesters, chemicals
cupboards, compressor plant, etc.). Equipment that is not required may be decommissioned in correct technical manner. It is the Lessee’s task to obtain official permits to operate the facilities. 

 

	 	•	 	 The Lessee is fully aware of the condition of the rental areas and recognizes these as conforming with the Agreement. At the Lessee’s wish this
Rental Agreement collates all previous rental agreements and supplements and replaces them. The agreements involved are: 

  

	 	•	 	 Rental agreement of Jan. 31/Feb. 19, 2003 o Supplement no. 1 of July 25/July 31, 2008 o Supplement no. 2 of July 29, 2008

  

	 	•	 	 Supplement no. 3 of August 21, 2008 

  

	 	•	 	 Exercise of the option of May 19, 2009, confirmation of May 27, 2009 

 

	 	•	 	 Supplement no. 4 of May 29, 2009 

  

	 	•	 	 Supplement no. 5 of Jan. 21/Jan. 24, 2011 

  

	 	•	 	 Supplement no. 6 of May 16/May 24, 2011 

  

	 	•	 	 Contract for renting parking spaces (outside) of June 10/June 20, 2011 

 

	 	•	 	 Contract of renting parking spaces (underground garage) of June 10/June 20, 2011 

 

	 	•	 	 Partial cancellation of outside parking spaces of Nov. 26, 2012. 

Additionally, the office space in INF 584, ground floor, right is rented. 

 

	 	•	 	 At variance with para. 1.4 the notice period to cancel use of the storeroom INF 583, 1st floor, is three (3) months to the end of the quarter.

  

	 	•	 	 The rental space in INF 584 ground floor, right, is taken over as seen, in non- renovated condition. When the Lessee vacates this space, it is to be
returned clean and tidy (swept). 

  

	 	•	 	 The deposit under the previous tenancy arrangement of € 59,000.00 will be credited against the new deposit. 

 

			
	Heidelberg, April 11, 2013	  	                Heidelberg, April 15, 2013
	(Place, date)	  	                (Place, date)
		
	/s/ Lotte Sønderbjerg	  	 //signature illegible, stamp of
 Technologiepark Heidelberg II GmbH & Co.
 KG//

		  	                            
Lessor
	 Lessee, represented by virtue

of power of representation entered
 in Register
of Companies or
 power of attorney

Name, signature, stamp
	  	

 Appendix 1 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and Ascendis
Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg” 
  

 
 Key: 

Gebäude = building 
 Flst. (Flurstück)
= cadastral unit 

 Appendix 1a to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 1 of 4 

 

 

 
 Key: 

Leerstand = Vacant 
 Rech. und Beratung =
Accounts and consultancy 
 Beruf und Kind = Profession and children 
 Without any warranty and acknowledgment of a legal duty. The delivery of this floor plan shall not give rise to a right to a rental agreement being concluded. The exact measurements are to be taken on the
building itself. 

 Appendix 1a to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 2 of 4 

 

 

 
 Key: 

Tiefgarage = Underground parking Abstellraum = Small 
 storeroom Treppe = Stairs 
 Lager = Storeroom Treppenhaus = 

Staircase Flur = Corridor Zählerraum = 

Meter room Batterie = Battery 
 Telekom =
Telecommunication 
 Büro = Office 

Annahme/Lager = Goods reception/storeroom 

Personal = Personnel facilities 
 Server = Server
Teeküche = 
 Pantry WC = toilet 

Haustechnik = utility room 
 Address: 69120
Heidelberg, Im Neuenheimer Feld 584, Untergeschoss (basement) 
 Without any warranty and acknowledgment of a legal duty. The delivery of this
floor plan shall not give rise to a right to a rental agreement being concluded. The exact measurements are to be taken on the building itself. 

 Appendix 1a to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 3 of 4 

 

 

 
 Key: 

Empfang = Reception desk 
 Büro = Office
Treppenhaus = Staircase 
 EDV = IT 

Labor = Laboratory Lager = 
 Storeroom Flur =
Corridor 
 Teeküche = Pantry 

Sekretariat = Secretary’s office 
 WC =
Toilet 
 Tür schliessen... = Door closes .... Aufzug = Elevator 
 Gard. = Cloakroom 
 Elektro = Electrical appliances 

Lager/Archiv = Storeroom/Archive 
 Address:
69120 Heidelberg, Im Neuenheimer Feld 584, Untergeschoss (basement) 
 Without any warranty and acknowledgment of a legal duty. The delivery of
this floor plan shall not give rise to a right to a rental agreement being concluded. The exact measurements are to be taken on the building itself. 

 Appendix 1a to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 4 of 4 

 

 

 
 Key: 

Besprechung = Meeting room Elektro = 
 Electrical
appliances Vorraum = Anteroom 
 Nebenzone... = Ancillary area (meeting room) Aufzug = elevator 

Büro = Office 
 Empfang = Reception desk

 Teeküche = Pantry 
 Kop./Server
= Photocopier/Server 
 WC = toilet Archiv = Archive Kopieren 
 = Photocopier Labor = Laboratory 
 Treppenhaus = Staircase 

Flur = Corridor 
 Address: 69120 Heidelberg, Im
Neuenheimer Feld 584, Untergeschoss (basement) 
 Without any warranty and acknowledgment of a legal duty. The delivery of this floor plan shall
not give rise to a right to a rental agreement being concluded. The exact measurements are to be taken on the building itself. 

 Appendix 2 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and Ascendis
Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg” 
 Ascendispharma 
  
 

 
 Received November 26, 2012, RNI GmbH 
 Ascendis Pharma GmbH |Im Neuenheimer Feld 584 | D-69120 Heidelberg 
 RN Immobilienmanagement GmbH

 Rhein-Neckar 
 Mr Claus Schumacher

 Im Neuenheimer Feld 584 
 69120
Heidelberg 
  

							
	From	  	E-mail	  	Direct line	  	Date
	Constanze El Rikabi	  	cr@ascendispharma.com	  	+49-6221-43853-0	  	November 26, 2012

 Declaration of purpose for rental property INF 584, ground floor, for TP GmbH 

Dear Mr Schumacher, 
 In order to obtain the
declaration of purpose from TP GmbH, we wish to provide you with the following information: 
  

	1)	The contracting partner is Ascendis Pharma GmbH; 

  

	2)	The company is a limited liability company, registered in the Commercial Register of the Mannheim local court (Amtsgericht) under No. HRB337385 with VAT ID No.
DE813586261; 

  

	3)	Purpose of the enterprise as stated in the shareholders’ agreement: research and development in the field of administering bioactive substances by means of
cleavable linkers along with associated activities; 

  

	4)	Ascendis Pharma GmbH is a wholly owned subsidiary of Ascendis Pharma A/S, headquartered in DK-2900 Hellerup; 

 

	5)	The company Ascendis Pharma GmbH currently has 27 employees, all of whom are employed at the location in Neuenheimer Feld 584 (TP); 

 

	6)	In our chemical, biochemical and analytical laboratories, preclinical research is carried out in the field of protein and peptide therapeutics of the second generation;

  

	7)	Using our Transcon technology, we are focused on the field of analytical and synthetic organic chemistry and bioconjugation. Our current drug candidates relate to the
therapy of endocrinological, cardiological and opthalmological diseases; 

  

	8)	No patients visit the premises; we only receive visitors in the ordinary course of business. 

 

					
	Sincerely,	 		 	
		 		 	Geschäftsführerin Lotte
	/s/ Harald Rau	 		 	Sønderbjerg Amtsgericht
	ppa. Dr Harald Rau	 		 	Mannheim Ascendis
	Wissenschaftlicher Leiter (Scientific Head)	 		 	Pharma GmbH HRB
	Ascendis Pharma GmbH	 		 	337385
		 		 	Sparkasse Heidelberg
		 		 	Kto. 9008861
		 		 	Blz 67250020
		 		 	Ust.-IdNr. DE813586261

							
	Commercial Register B of the Local Court of Mannheim (Amtsgericht)	  	No. of company:	  	HRB 337385
		  	Information retrieved on 2 January 2013, 13:33	  	Page 1 of 2	  	
	Appendix 2a to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583
(1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”

  

													
	 No. of entry
	  	 a) Company
 b) Headquarters, branch, domestic business
address, person authorized to accept delivery,
branch offices

c) Purpose of the
enterprise
	  	Share
capital	  	 a) General representation rules

b) Management Board,

management body, managing

directors, personally liable

partners, managers, authorized

persons and special authority to
 represent the company
	  	 Prokura (full

commercial authority
under German law)
	  	
a) Legal form, start of activity, articles of
 association or shareholders’ agreement
b) Other legal relationships
	  	 a) Date of entry
 b) Comments

	1	  	 2
	  	3	  	 4
	  	 5
	  	 6
	  	 7

	1	  	 a) Complex Bioystems GmbH
  

b) Heidelberg
  
 c) Research and development of chemical processes to optimize biological macro-molecules
	  	EUR49,000.00	  	 a) If only one managing director (Geschäftsführer) is appointed, he is the sole representative. If several managing directors
are appointed, two shall represent the company jointly or one together with a holder of full commercial authority (Prokurist).
  

b) Managing Director (Geschäftsführer):
 Dr Vetter, Dirk, Heidelberg, *13 Oct. 1963, with authority to enter into legal transactions with himself on behalf of the company and in his own name or as a representative of a third
party.
	  		  	 a) Private limited liability company under German law (GmbH)
 Shareholders’ agreement of 18 Nov. 2002, most recently amended on 26 April 2005
	  	 a) 20 Feb. 2006

Pallmann
  
 b) This sheet has been transferred to an IT system, replacing the past register sheet. Clearance was given on 20 Feb. 2006.
 Date of first entry:
 22 Nov. 2002
 Shareholders’ agreement: special volume sheet 325 ff.
  
 Amendment resolution:
 special volume sheet
 265 ff.

	2	  	 a) Company name amended; now trading as Ascendis Pharma GmbH

 
 c) Purpose of the enterprise amended to read as follows: Research and development in
the field of administering bioactive substances by cleavable linkers along with associated activities.
	  		  		  		  	 a) At the shareholders’ meeting of 2 January 2008, a resolution was adopted to amend the shareholders’ agreement in Arts. 1
(1) (Firma/company name), 2 (1) (Gegenstand des Unternehmens/purpose of the enterprise), 4 (Bekanntmachungen/announcements), 5 (1) (Stammkapital/ Share capital), 7 (5) (Gesellschafterversammlung/shareholders’ meeting), 8 (2) (Zuständigkeit
der Gesellschafterversammlung/competence of the shareholders’ meeting) 9 (Gesellschafts- beschlüsse/company resolutions), 11 (Geschäftsführung/corporate governance), 14 (Ergebnisverwendung/appropriation of retained profit), 16
(Finanzplan..../financial plan, previously rights to information and duties of disclosure), and 35 (Wettbewerbsverbot/prohibition on competition) as well as the deletion in full of Arts. 6, 10, 17 to 32 and 34.

 
 Arts. 7 – 9 have been renumbered into Arts. 6-8, Arts. 11 – 16 into Arts.
10-14, Art. 33 into Art. 15 and Arts 35-36 into Arts. 16-18.
	  	a) 17 April 2008 Ley
	3	  	b) Pursuant to Sect. 3 of EGGmbGG (introductory Act of the German Act on private liability companies) supplemented ex officio	  		  	b) No longer managing director (Geschäftsführer):	  	Individual signing powers (Prokura): Dr. Rau, Harald, Dossenheim, *25 April 1970	  		  	a) 10 Jan. 2012 Trunner

							
	Commercial Register B of the Local Court of Mannheim (Amtsgericht)	  	No. of company:	  	HRB 337385
		  	Information retrieved on 2 January 2013, 13:33	  	Page 2 of 2	  	
	Appendix 2a to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583
(1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”

  

													
	 No. of entry
	  	 a) Company
 b) Headquarters, branch, domestic business
address, person authorized to accept delivery,
branch offices

c) Purpose of the enterprise
	  	Share
capital	  	 a) General representation rules

b) Management Board,
management body, managing
directors, personally liable
partners, managers, 
authorized
persons and special authority to
represent the company
	  	Prokura 
(full
commercial authority
under German law)	  	
a) Legal form, start of activity, articles of
 association or shareholders’ agreement
 b) Other legal
relationships
	  	 a) Date of entry

b) Comments

	1	  	 2
	  	3	  	 4
	  	5	  	 6
	  	 7

		  	 Business address:
 Im
Neuenheimer Feld 584, 69120 Heidelberg
	  		  	 Dr. Vetter, Dirk, Heidelberg, *13 Oct. 1963
 Appointed as:
 managing director
 (Geschäftsführer)
 Sonderbjerg, Lotte, Frederiksberg

C/Denmark, *5 Jan. 1961
 Individually entitled to
represent the company with authority to enter into legal transactions with herself on behalf of the company and in her own name or as a representative of a third party.
	  		  		  	
	4	  		  		  		  		  	a) At the shareholders’ meeting of 19 March 2012, a resolution was adopted to amend the shareholders’ agreement in Art. 7 (Zuständigkeit der
Gesellschafterversammlung/competence of the shareholders’ meeting) and Art. 11 (Jahresabschluss/annual financial statements)	  	 a) 29 Mar. 2012

Trunner

 Appendix 3 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 1 of 2 

 

 Allplan 
  

			
	Project:	  	584 ground floor rental area Ascendis
	Author:	  	Schmidt
	Date/time:	  	8 Jan. 2013 / 12:07
	Note:	  	

  

													
	 Type of use
	  	 Designation
	  	 Function
	  	Area	 	  	Net internal Area, NGF [m2]	 
					
		  	Ground floor Bt. 2	  	Floor space (gross)	  				  	 	735.132	  
		  		  		  				  	  
	  
	 
		  	 Total
	  		  				  	 	735.132	  
		  		  		  				  	  
	  
	 
	 Total
	  		  		  				  	 	735.132	  
		  		  		  				  	  
	  
	 
	 Grand total
	  		  		  				  	 	735.132	  
		  		  		  				  	  
	  
	 
		
	 	  	 Type of use
	 
	 	  	 NF
	  	 TF
	  	VF	 	  	Total	 
	 Net Internal Area, NGF [m2]
	  	0.00	  	0.00	  	 	0.00	  	  	 	735.13	  

 Appendix 3 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 2 of 2 

 

																											
	 	 	 	  	Rental /
general
area (100% net)	 	  	Share
+ communal area
%	 	  	Share of communal
area + 
6%
m2	 	 	Rental area
(106%)	 	  	Storage area	 	  	Total rental area	 
		 	 Total rental area
	  	 	523.59 m2	  	  				  				 	 	555.01 m2	  	  	 	555.01 m2	  
	
	 CALCULATION STATUS 16 Sept. 2002
	 
	 2nd floor
	 	 Rental area West –

free
	  	 	BT1	  	  	 	413.05 m2	  	  	 	85.59	% 	 	 	35.35 m2	  	  	 	475.30 m2	  	  	 	475.30 m2	  
		 	Project M	  	 	BT1	  	  	 	69.52 m2	  	  	 	14.41	% 	 	 	5.95 m2	  	  	 	80.00 m2	  	  	 	80.00 m2	  
		 	Communal area	  	 	BT1	  	  	 	41.30 m2	  	  	 	100.00	% 	 				  				  			
		 		  				  	  
	  
	 	  				 				  	  
	  
	 	  	  
	  
	 
		 	 TOTAL RENTAL AREA
	  				  	 	523.87 
m2	  	  				 				  	 	555.30 
m2	  	  	 	555.30 
m2	  
		 		  				  	  
	  
	 	  				 				  	  
	  
	 	  	  
	  
	 

 Architekten Kuhlmann 
 69115 Heidelberg, Vangerowstr. 14 
 Tel.: 06221/12313 Fax 06221/164547 

Building BT1 021002 2nd floor BT 10 2 10 02 
 Print date: 8 Oct. 2002 

 Appendix 4 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 1 of 2 

 

 Parking spaces 
 Building 515, front 
  
  

 
 Parking spaces 515, front 

Status as of: //Stamp: 30 Jan. 2013// 

 Appendix 4 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 2 of 2 

 

 Underground car park 

Building Im Neuenheimer Feld 584 
  

 
 

 
  

			
	Top - > 	  	<.. ENTRANCE
		
	Bottom ->	  	no longer apply

  

 Appendix 5 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 1 of 3 

 

 § 1 Running costs 

 

	(1)	Running costs are those costs incurred by the owner or the holder of the heritable building right on an ongoing basis by virtue of ownership or a heritable building
right to the plot of land or by the due and proper use of the building, ancillary buildings, equipment, facilities and the plot of land itself. Non-cash contributions and works services rendered by the owner or the holder of the heritable building
right under the heritable building right may be recognised at the amount that could be claimed for a comparable service by a third party, in particular by a contractor; the value added tax of such third party must not be recognised.

  

	(2)	The running costs do not include the following: 

 1. The costs of staff and facilities needed to manage the building, the costs of supervision, the value of administrative services performed by the lessor himself, the costs of statutory or voluntarily
audits of the annual financial statements and the costs of management (administrative costs), 
 2. The costs incurred during the
period of use in order to maintain intended use and duly eliminate any constructional or other deficiencies occurring through wear-and-tear, age and the effect of weather conditions (maintenance and repair costs). 

§ 2 Schedule of running costs 
 Running costs as contemplated by § 1 are the following: 
  

	1.	ongoing public encumbrances on the real estate, specifically the property tax; 

 

	2.	the costs of water supplies, 

which include the costs of water consumption, base fees, costs of renting or otherwise obtaining the use of water meters, the costs of
using them, including the costs of calibration, preparing accounts and allocating charges, the costs of servicing water flow regulators, the costs of operating an in-house supply facility and a water purification plant including the purifying
materials; 
  

	3.	the costs of drainage; 

 which
include charges for draining the building and land, the costs of operating an appropriate non-public plant and the costs of operating a drainage pump; 
  

	4.	the costs 

 a) of running the
central heating plant plus the flue gas plant, which include the costs of fuels used and their delivery, the costs of electricity to operate the system, costs of attending to, monitoring and servicing the plant, regular inspection to ensure the
plant is in working order and safe to operate including adjustments by a qualified worker, cleaning the plant and the service room, the costs of having measurements taken in compliance with the German Federal Act on Control of Emissions
(Bundes-Immissionsschutzgesetz), the costs of renting or otherwise obtaining the use of equipment to record consumption and the costs of using equipment to record consumption including the costs of calibration, preparing accounts and allocating
charges 
 or 
 b) the costs of operating the central fuel supply plant, 
 which includes the costs
of fuel consumption and delivery, the costs of electricity to operate the system, the costs of monitoring the plant, the costs of cleaning the plant and service room 
 or 
 c) the independent commercial supply of heating, including from plants as
contemplated in letter a, which includes payment for the supply of heating and the costs of operating the house facilities which belong to the system in accordance with letter a 

 Appendix 5 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 2 of 3 

 

 or 
 d) cleaning and servicing heating systems that serve one individual floor and single gas burners, which includes the costs of removing water deposits and combustion residues in the plant, the costs of
regular inspections to check that the plant is in working order and safe to operate and, in this connection, hiring a qualified worker to adjust any settings and the costs of taking measurements in compliance with the German Federal Act on Control
of Emissions (Bundes-Immissionsschutzgesetz); 
  

	5.	the costs 

 a) of operating the
central plant for the supply of hot water, 
 which includes the costs of supplying water in accordance with no. 2, unless
already included, and the costs of heating water in accordance with no. 4 letter a 
 or 

b) the independent commercial supply of hot water, including from plants as contemplated by letter a, 

which includes payment for the supply of hot water and the costs of operating the house facilities which belong to the system in
accordance with no. 4 letter a 
 or 
 c) cleaning and servicing hot water devices, 
 which includes the costs of removing
water deposits and combustion residues inside the devices and the costs of regular inspections to check that they are in working order and safe to operate and, in this connection, hiring a qualified worker to adjust any settings; 

 

	6.	the costs of integrated heating and hot water plants 

 a) in connection with central heating plants as described in no. 4 letter a and in accordance with no. 2 unless already included therein, 

or 
 b) in
connection with the independent commercial supply of heating as described in no. 4 letter c and in accordance with no. 2 unless already included therein, 
 or 
 c) in connection with integrated plants to supply individual floors with heat
and hot water as described in no. 4 letter d and in accordance with no. 2 unless already included therein, 
  

	7.	the costs of operating elevators and service lifts, 

 which include the costs of electricity to operate them, the costs of supervising, attending to, monitoring and servicing the lifts, regular inspections to check they are in working order and safe to use,
including any necessary adjustments by qualified workers and cleaning the lifts; 
  

	8.	 the costs of street cleaning and waste removal; street cleaning costs include the charges levied for public cleaning services and the costs of any
relevant non-public services; the costs of waste removal specifically include the charges levied for the provision of waste collection services, the costs of any relevant non-public services, the operating costs of the waste compactors, waste chutes
and pneumatic refuse collectors and the costs of refuse recording systems including the costs of preparing accounts and allocating expenses; 

 Appendix 5 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 3 of 3 

 

	9.	the costs of cleaning and pest control, 

 cleaning the building includes the costs of cleaning the parts of the building used by all tenants, such as entranceways, corridors, stairs, cellars, attic spaces, laundry rooms, the elevator cabins

  

	10.	the costs of looking after the gardens, 

 these include the costs of tending to the areas laid out as gardens, including planting new plants and shrubs if necessary, care of playgrounds including the renewal of sand and looking after squares,
entranceways and driveways that are not open to public traffic; 
  

	11.	the costs of lighting; 

 these
include costs of electricity for the outside lights and lighting in the parts of the building used by all tenants, such as entranceways, corridors, stairs, cellars, attic spaces, and laundry rooms; 

 

	12.	the costs of chimney sweeping; 

these include the fees for sweeping as laid down in the schedule of fees for the region unless not already treated as costs in connection
with no. 4 letter a; 
  

	13.	the costs of property and liability insurance, 

 these specifically include costs for insuring the building against fire, storm & tempest, flood and other natural hazards, glass insurance, liability insurance for the building, the oil tank and
the lifts; 
  

	14.	the costs of janitor services, 

these include the wages, social insurance contributions and all cash-equivalent benefits which the janitor receives for his services from
the owner or holder of the heritable building rights which do not relate to maintenance, repair, renewal, redecoration work or administration of the building; whenever the janitor has performed certain tasks, the costs for his work may not be billed
as costs pursuant to nos. 2 to 10 and 16; 
  

	15.	the costs 

 a) of operating the
joint antenna installation, 
 these include the costs of electricity to operate the system and costs of regular inspections to
check it is in working order, including any adjustments required by a qualified worker or the fees for the use of an antenna installation that does not belong to the building and the fees which arise under copyright law for the onward transmission
of cable broadcasts, 
 or 
 b) of operating a private distribution system linked to a broadband cable network; this includes the costs corresponding with letter a, plus the regular monthly base fees for the broadband cable
connections; 
  

	16.	the costs of operating the laundry facilities, 

 this includes the costs of electricity to operate the facilities, the costs of supervising, servicing and cleaning the facilities, regular inspections to check they are in working order and safe to
operate and the costs of water supplies in accordance with no. 2 unless these have already been included therein; 
  

	17.	other running costs, 

 which
include running costs as contemplated by § 1 that are not encompassed by nos. 1 to 16. 

 Appendix 6 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and Ascendis
Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 1 of 1 
 Alteration work re: para. 9.3: on rental area INF 584, ground floor right, south (laboratory side) 
  

	 	1.	Installation of a ladies’ toilet in the room designated as “Kühlraum/Cold storage” 

 

	 	a.	a washbasin, a toilet, floor and walls tiled to the ceiling, lowered ceiling with built-in downlights, primary walling work up to approx. 1.5 m

  

	 	2.	Installation of a gents’ toilet in the room designated as “Analytik 3/Analytics 3” 

 

	 	a.	as above, but a washbasin, a toilet and a urinal. 

  

	 	3.	Installation of an office in the room designated as “Synthetische Chemie/Synthetic chemistry”. 

 

	 	a.	Delineated by three plasterboard walls reaching to the bare ceiling, planked on both sides, and a wall serving as a room divider to the break area. This office will be
floored with carpeting (Anker Albu 618-30). Ceiling: mineral fibre ceiling with installed luminaires. Access is through the existing door to the corridor. 

  

 
 

 
 Lager = Storeroom 
 Labor = Laboratory 
 Flur = Corridor 
 There is no obligation to restore the status quo ante prior to the conversion at a later date. 

 Appendix 7 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and Ascendis
Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 1 of 1 
  

					
	Technologiepark Heidelberg Postfach 10 55 20 69045 Heidelberg	 	Marktplatz 10
	Technologiepark Heidelberg II GmbH & Co. KG	 	69117 Heidelberg
	c/o RN Immobilienmanagement GmbH Rhein-Neckar	 	Campusbüro
	Im Neuenheimer Feld 584	 	Im Neuenheimer Feld 582
	69120 Heidelberg	 	69120 Heidelberg
		 	Tel.	 	+49.6221.50257-00
		 		 	+49.6221.50257-10
		 	Fax	 	+49.6221.50257-11
		 	E-Mail techologiepark@heidelberg.de
		 	Web techologiepark-heidelberg.de

 3 December 2012 
 Technologiepark Heidelberg - Biopark, 1. BA 
 Approval of the conclusion of a rental
agreement 
 re: lease to Ascendis Pharma GmbH 
 Dear Sir or Madam, 
 On the basis of the existing contractual arrangements between Technologiepark
Heidelberg II GmbH & Co. KG and Technologiepark Heidelberg GmbH, I agree to the lease with the above-mentioned contracting partner after receipt of the declaration of purpose on behalf of Technologiepark Heidelberg GmbH. 

 

	
	Sincerely,
	
	/s/ Dr. André Domin
	Dr. André Domin

  
 ... 

 Appendix 8 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and Ascendis
Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg” 
 Sender: Ascendis Pharma GmbH                      

 

			
	Technologiepark Heidelberg II	  	Ascendis Pharma GmbH (stamp)
	GmbH & Co. KG	  	Im Neuenheimer Feld 584
	Im Neuenheimer Feld 584	  	D-69120 Heidelberg
	69120 Heidelberg	  	Tel.: +49 6621 43 85 3-0
		  	VAT ID: DE813586261
		  	www.ascendispharma.com

 Property: Technologiepark Heidelberg II GmbH & Co. KG Direct debit authorisation 

I/We hereby authorise the Lessor to have the rentals and service charges owed for the above-mentioned rental area until revocation debited to 

my/our account no.: 900 88 61, bank code: 672 500 20 
 with (name and designation of bank/savings bank): Sparkasse Heidelberg 
 Direct
debit authorisation valid as of (first debit): 05/2013. 
 If my/our account does not have the necessary cover, the credit institution keeping
the account shall not be obliged to make the relevant payment. In the event of a failed debit, the Lessor shall be entitled to reject the direct debit authorisation. 
  

	
	(Place, date) Heidelberg, 11 April 2013
	
	/s/ LOTTE SØNDERBJERG
	
	//Signature of Lotte Sønderbjerg//
	(Name and address of the account holder)
	
	//Stamp//
	Ascendis Pharma GmbH
	Im Neuenheimer Feld 584
	D-69120 Heidelberg
	Tel.: +49 6221 43 85 3-0
	 VAT ID: DE813586261

www.ascendispharma.com

 Status as of: May 2011 

 Appendix 9 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and Ascendis
Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, page 1 of 1 (translation extends to 2 pages)  

Please note before use! 
 Brief instructions for use of the Parklift 402 – 170 
 Safety
regulations 
  

	 	•	 	 The facility is solely intended for use by passenger cars! No access is permitted other than from the drive-in side! 

 

	 	•	 	 Access to the pit, climbing up to the raised platform and working on the platforms is prohibited! 

 

	 	•	 	 Before parking and removing a car, the platform must be fully lodged in its final upper or lower position. 

 

	 	•	 	 When moving the platform, ensure that neither you nor any other persons or objects are in the within the range of movement of the facility!

  

	 	•	 	 In the case of dual parklift facilities, for technical stability reasons never park or remove two cars simultaneously but only one at a time!

  

	 	•	 	 When parking and removing a car always switch on the garage and car lights! 

 

	 	•	 	 Avoid collisions: 

  

	 	•	 	 between your car and the facility when parking or removing a car! 

 

	 	•	 	 when moving the platform between the car and the facility or installed components! 

 

	 	•	 	 Never reverse into a parking bay! 

  

	 	•	 	 Drive onto platform at a measured pace! 

  

	 	•	 	 Look out for abutting edges or potential tripping hazards when on the platform! 

 

	 	•	 	 No persons may be conveyed on the platform! 

  

	 	•	 	 Ensure that no passengers are in the car when parking or removing it! 

 

	 	•	 	 Always remove keys after operation to avoid unauthorised use! 

 

	 	•	 	 Pay attention to children and pets: keep them away from the parking system! 

 Danger to life and limb! 
 Unauthorised access to the pit is prohibited! 

 

	 	•	 	 The following must be ensured without fail before work is carried out on park systems by trained personnel: 

 

	 	•	 	 Lower the facility completely! 

  

	 	•	 	 Switch off lockable main switch and lock it so it cannot be activated on its own! 

 

	 	•	 	 Only proceed under raised platforms if these have been secured to prevent them from being lowered even in the event of a tremor or vibration! Secure
neighbouring facilities as well! 

  

	 	•	 	 No work may be carried out on hydraulic equipment by staff without special training! 

Operating instructions 

Parking 
 Note the maximum permissible
weight and dimensions for a car before parking. Remove residual snow and ice from the car in front of the garage. Remove roof racks and ski holders. Push in or remove aerial. Unload baggage; close boot. Do not use the platform with snow
chains or spikes. Always position the car on the platform in such a manner as to ensure that no vehicle parts stand out from the platform at the rear or either side. Place positioning aid depending on the vehicle type in question. 

Positioning aid upper platform: 
 Place
forward wedges directly in front of the front tyres. 
 Engage first gear (automatic vehicles: gear lever position P). Pull up parking brake.
Switch off engine and close doors. 

 Positioning aid, lower platform: 
 Place forward wedges directly in front of the front tyres. Do not drive over the forward wedges. 

Leaving the parking space 
 Look out for
persons and objects when backing out into the driving lane. 
 //2nd column, right// 
 Controls 

Press EMERGENCY SWITCH in an emergency! 

EMERGENCY SWITCH can be unlocked by turning the button in a clockwise direction. 
 Raising the platform 
 Key: 

 

	•	 	 insert 

  

	•	 	 turn to the right and hold 

  

	•	 	 release. Once the final position is reached, it will automatically turn back. 

 

	•	 	 remove. 

 Lowering the
platform 
 Key: 
  

	•	 	 insert 

  

	•	 	 turn to the left and hold 

Attention: Danger of pinching! 
 Key:

  

	•	 	 release. Once the final position is reached, the key will automatically turn back. 

 

	•	 	 remove 

 Automobile data
(standard facility with a parking space width of 2.30m) 
 //Right-hand column// 

 

			
	maximum length	  	5,000mm
	maximum width (excl. external rear-view mirror)	  	1,900mm
	maximum height	  	1,500mm
	maximum weight	  	2,000kg
	maximum wheel load	  	500kg

 On special-size facilities refer to the lift force information sign on the platform. 

Cars with lowered chassis and cars with front spoilers can only be parked at the driver’s own risk. Cars or station wagons that exceed the
dimensions specified in the illustrations may be damaged when parked or when moving the platform. 
  

			
	WÖHR AUTO PARKSYSTEME	  	Otto Wöhr GmbH
		  	Leonberger Str. 77
		  	D-71292 Friolzheim

 In the event of damage or malfunctions, please notify your facility management without delay! You may also address any
enquiries about technical problems to our customer service. 
 //Left-hand column// 

Passenger Car 
 Automobiles over 1.50m in
height and station wagons must not be parked on the upper platform. Cars and station wagons up to 1.50m in height may be parked on the lower platform. 
 Station wagon 

 Appendix 10 to the Rental Agreement between Technologiepark Heidelberg II GmbH & Co. KG and
Ascendis Pharma GmbH for areas under lease “Im Neuenheimer Feld 583 (1st floor) and 584 (basement, ground floor and 2nd floor), 69120 Heidelberg”, 10 pages 
  

			
	Technologiepark Heidelberg	  	WISAG
	Buildings 581, 582, 583, and 584	  	Facility Management            

 Fire Regulations 
 For Technologiepark Heidelberg 
 Buildings 581, 582, 583, and 584

  

					
	January 2006	 		 	Prepared by: WISAG FM

							
	 Technologiepark Heidelberg
 Buildings 581, 582, 583, and 584
	 		 		 	 WISAG
 Facility
Management

  

 Overview 

 

					
	1	 	Safety equipment and facilities, buildings 581, 582, 583, 584	  	Page 3
			
	2	 	What to do in the event of fire	  	Pages 4-5
			
	3	 	Fire-fighting and safety measures	  	Page 6
			
	4	 	Portable fire extinguishers	  	Pages 7-8
			
	5	 	Preventive fire protection	  	Page 9

  

					
	January 2006	 	Page 2	 	Prepared by: WISAG FM

							
	 Technologiepark Heidelberg
 Buildings 581, 582, 583, and 584
	 		 		 	 WISAG
 Facility
Management

  

	1	SAFETY EQUIPMENT AND FACILITIES IN BUILDINGS 581 to 584 

 Buildings 581 - 584 are equipped with smoke detectors that automatically trigger an alarm to the fire alarm system and to the Heidelberg fire brigade. Wall-mounted fire hydrants and fire extinguishers
are located on each floor; please refer to the escape route plan prominently displayed in the corridors on each floor for their exact location. Each of these wall-mounted hydrant cabinets contains the following 

 

					
		  	 •        a fire
extinguisher
  

•        a fire extinguishing hose under
constant water
pressure with 30m in hose

 The manual fire alarms (push-button alarms) are located in the corridors and staircases.

 In the event of a power failure a battery system is automatically activated to ensure the functionality of key technical
equipment such as escape route and emergency lighting. 

  

					
	January 2006	 	Page 3	 	Prepared by: WISAG FM

							
	 Technologiepark Heidelberg
 Buildings 581, 582, 583, and 584
	 		 		 	 WISAG
 Facility
Management

  

	2	HOW TO BEHAVE IN THE EVENT OF FIRE 

 Remain calm and do not panic! 
 Act quickly! 

When reporting a fire, the following information must be included: 

 

	 	•	 	 WHO is reporting? Mention your name. 

  

	 	•	 	 WHAT has happened? 

  

	 	•	 	 WHERE did it happen? Specify the city, street, building, floor, room number. 

 

	 	•	 	 WHAT assistance is required? People in danger, especially hazardous area. 

 

	 	•	 	 WAIT for queries? Do not hang up before the fire brigade centre ends the telephone call. 

First report – then extinguish a fire! 

Do not use elevators due to danger of asphyxiation! 

 

	2.1	General notes regarding statutory obligations: 

 “Whoever notices or learns about a fire is obliged to report it without delay.” 
 A fire can be reported on each floor using the installed press-button alarms or by calling the fire brigade (emergency number 112). 

After that, call the facility management and control room using the following telephone numbers 

Facility management 06221/650620 65292-10 

0174/3465358. 

“According to the German Civil Code/BGB, 
 every citizen is required to report an 
 emergency and to give
assistance.” 
  

	2.1.1	The Security staff office is responsible for preventive fire protection in the rental area DKFZ as well as for emergency personnel on call and in charge of operations
in the event of an emergency. If a fire breaks out, the fire brigade arriving on the scene takes over responsibility for operations. 

  

					
	January 2006	 	Page 4	 	Prepared by: WISAG FM

							
	 Technologiepark Heidelberg
 Buildings 581, 582, 583, and 584
	 		 		 	 WISAG
 Facility
Management

  

	2.2	The tasks of the Fire Protection Officer (Brandschutzbeauftragter) include the following in particular: 

 

	2.2.1	The need to explore and acquaint himself with his area of responsibility and to rescue persons who may be in danger. 

 

	2.2.2	The Fire Protection Officer may make attempts to extinguish fires at his discretion; portable fire extinguishers or wall hydrants are to be used to this end.

  

	2.2.3	An evacuation of the building is carried out by the officers in charge of the fire brigade or police. 

In an acute emergency, the Fire Protection Officer is authorised to evacuate his particular area. 

 

	2.2.4	The Fire Protection Officer is also responsible for other incidents, such as explosions and bomb threats, etc. 

 

	2.3	In case of an incident, each person involved is required to observe the following general rules: 

 

			
	2.3.1	  	Keep calm!
		
		  	 Make an effort to calm down excited persons!

Make an attempt to prevent rash actions!        

  

	2.3.2	Establish immediately whether human lives are in danger! Rescue work takes priority over fire-fighting or protecting property! 

 

	2.3.3	Proceed through smoky rooms by bending down or crawling on all fours. Breathable air and better vision mostly exist close to the floor! Protecting the mouth and nose
with a wet cloth can also be helpful! There are a number of signposts indicating rescue and escape routes on each floor. 

 Staircases are closed and protected against smoke by means of fireproof locks. Adequate information on emergency exits is also provided on the basement floors. 

 

	2.3.4	Endangered persons must be notified without delay and assistance provided if necessary. 

 

	2.3.5	In the event of an alarm being sounded (meaning evacuation of the building), all tenants and visitors are required to gather at the designated assembly point. This
assembly point may be left only once the firemen in charge give their approval. 

  

					
	January 2006	 	Page 5	 	Prepared by: WISAG FM

							
	 Technologiepark Heidelberg
 Buildings 581, 582, 583, and 584
	 		 		 	 WISAG
 Facility
Management

  

	3	FIRE-FIGHTING AND SAFETY MEASURES 

  

	3.1	Use means and resources available to fight a fire until the arrival of the fire brigade. Use portable fire extinguishers or fire hoses from the wall hydrants. Take
fire-fighting measures only if you do not endanger yourself in the process. 

 If possible, easily flammable
objects must be removed from the vicinity of the fire. If the initial attempts to extinguish a fire happen to fail, then close all doors and leave the site of the fire for a safe location! 

On arrival of the fire brigade, the head of operations of the fire brigade will be in charge. His instructions must be obeyed without
fail! 
  

	3.2	In case of a fire, the staircases and escape routes must be protected from build-up of smoke. For this reason, please ensure that fire protection doors and doors of
smoke compartments are closed at all times. 

 The function of automatic closure of such doors must be guaranteed
at all times. Defects must be reported to the facility management without delay. 

  

					
	January 2006	 	Page 6	 	Prepared by: WISAG FM

							
	 Technologiepark Heidelberg
 Buildings 581, 582, 583, and 584
	 		 		 	 WISAG
 Facility
Management

  

	4	Portable fire extinguishers 

 The correct use of portable fire extinguishers is also subject to safety rules that must be observed, e.g. when extinguishing fires involving electrical equipment. 

 
 

 
 1 m minimum distance 
 Water and electricity are a hazardous combination and may even lead to terminal injuries in unfavourable conditions. For this reason it is essential to keep a certain safety distance when using any fire
extinguishers. In the case of electrical equipment with a voltage in excess of 1,000 V, only specially trained skilled personnel may extinguish a fire. 
 Fire extinguisher types and fire classes 
 The powder extinguishers
located on each floor are suitable for fires involving solid and liquid materials: 
 A- solid materials, e.g. paper, cardboard,
plastics, PCs, printers, photocopiers, furniture 
 B- liquid materials, e.g. solvents, enamels, oils, paraffin, small electrical
appliances 
 The Carbon dioxide extinguishers in laboratories are suitable for fires involving liquid materials:

 B- liquid materials, e.g. solvents, enamels, oils, paraffin, small electrical appliances 

  

					
	January 2006	 	Page 7	 	Prepared by: WISAG FM

							
	 Technologiepark Heidelberg
 Buildings 581, 582, 583, and 584
	 		 		 	 WISAG
 Facility
Management

  

	4.1	Using portable fire extinguishers 

 Correct use of portable fire extinguishers 
 The following advice should be
noted in order to achieve a speedy success of fire extinguishing measures: 
  

					
	 ZH 1/112
	  	 CORRECT
	  	 WRONG

			
	Fight fire with the wind.	  		  	
			
	Extinguish extensive fires by starting at the flame root from front to back!	  		  	
			
	Extinguish dripping and liquid fires from top to bottom!	  		  	
			
	Extinguish wall fires from bottom to top!	  		  	
			
	Use an adequate number of fire extinguishers at the same time, not consecutively!	  		  	
			
	Watch out for re-ignitions!	  		  	
			
	Do not return fire extinguishers to their brackets after use. Have them refilled!	  		  	

  

					
	January 2006	 	Page 8	 	Prepared by: WISAG FM

							
	 Technologiepark Heidelberg
 Buildings 581, 582, 583, and 584
	 		 		 	 WISAG
 Facility
Management

  

	5	PREVENTIVE FIRE PROTECTION 

  

	5.1	Escape routes, corridors, anterooms to elevators, stairs, doors, emergency exits and power distribution rooms must be kept clear at all times. Fire-proof and
fire-resistant doors must not be kept open using wedges or similar items! 

  

	5.2	Cleaning service companies commissioned by the tenant must dispose of waste immediately in the containers made available for this purpose. In the areas designated under
5.1, no waste or cardboard material or any other items may be placed in provisional storage. 

  

	5.3	Portable fire extinguishers or fire hoses from the wall hydrants may be used to extinguish incipient fires. 

 

	5.4	There is an absolute ban on smoking in all buildings. 

  

	5.5	No electric kettles and the like may be used outside the pantries. Electrical appliances in pantries must be placed in a stable position (to ensure that they cannot
fall over) on a non-flammable base (e.g. stone). Only appliances bearing the VDE certification label may be used. 

  

	5.6	Very special care must be exercised when using welding, cutting and soldering equipment, and the relevant accident prevention regulations must be complied with.

  

	5.7	Custody and storage of flammable liquids is only permissible in the safety cabinets provided to this end. The maximum permissible size of the containers placed in
storage must not exceed a volume of 10 litres in the case of unbreakable containers (e.g. stainless steel containers) and a volume of 2.5 litres in the case of fragile containers (e.g. glass). 

In laboratories and workshops, the maximum container size for storage outside safety cabinets, for fragile containers (e.g. glass) is 1
litre, and for unbreakable containers (e.g. HDPE) 2.5 litres. In this connection, the total volume of flammable liquids is to be confined to daily requirements. 
  

	5.8	For reasons of preventive fire protection, the rooms in the building must be subjected to occasional inspections by the relevant public authority. The rental areas must
be kept accessible to such inspections during the normal operating hours. 

  

	5.9	These fire regulations are a preventive fire protection measure by order of the competent public authority. Tenants of this building are required to familiarise their
employees with these fire regulations. New employees of the tenant must be given a due and proper briefing by the tenant on the special characteristics of the building (with guidance on the location of fire alarm and extinguishing equipment as well
as escape routes). 

  

					
	January 2006	 	Page 9	 	Prepared by: WISAG FM

  
 

 
 Key: 

Bau = Building

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]